close

December 2021

Prescription drugs

An order for the distribution of fake prescription drugs

MANHATTAN, Kansas (WIBW) – After the RCPD warned residents of the dangers of fake prescription drugs and fentanyl on Thursday, a man was arrested for distributing drugs on Friday.

the Riley County Police Department said officers arrested Austin Dowling, 28, of Manhattan, for distributing controlled substances that caused an overdose in April. The alleged substances – Oxycodone and Fentanyl.

RCPD shows the difference between fake and real Oxycodone(RCPD)

The RCPD said an arrest warrant was issued for Dowling during an April 2021 opioid-related overdose investigation in Manhattan.

The officer said he arrested Dowling after he was found driving near the intersection of Valleywood Dr. and Barnes Rd. And was taken into custody just before 11 a.m.

The RCPD said Dowling was arrested on warrant on two counts of distributing possession with intent to distribute a controlled substance, distribution of a controlled substance causing grievous bodily harm and two counts of using a medium. communication for a drug transaction.

Dowling was also arrested on two additional warrants for breach of probation and failure to appear. He is currently confined to Riley Co. jail with a total bond of $ 116,000.

Copyright 2021 WIBW. All rights reserved.

read more
Prescription drugs

2021 Prescription Drug Market Size Analysis by Major Companies and Forecast to 2028

New Jersey, United States, – Market Research Intellect has been analyzing the prescription drug technology and markets since 2018. Since then, through the analysis of company research, we have been very close to the latest research and market developments.

In addition, Market Research Intellect works closely with many clients to help them better understand technology and the market environment and develop innovation and commercialization strategies.

Market Research Intellect offers extensive expertise in analyzing the prescription drug market. We have been in this industry for 20 years and have closely followed the rise and / or fall, success and / or disappointment of many emerging technologies during this time.

This gives us a unique eye of experience when it comes to analyzing emerging technologies in electronic materials. This is very important as it helps to build a realistic market and technology roadmap that reflects the true potential of the technology based on its intrinsic characteristics and the true level of technology and business challenges it faces.

Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=202717

Further, the market revenue by region and country is provided in the Prescription Drugs report. The report’s authors also shed light on common business tactics adopted by players. The major players in the global bPrescription Drugs Market and their complete profiles are included in the report. Additionally, investment opportunities, recommendations, and current trends in the global Prescription Drug market are mapped by the report. As a result of this report, major players in the global Prescription Drugs Market will be able to make right decisions and plan their strategies accordingly to stay ahead of the game.

The competitive landscape is an essential aspect that any key player should be aware of. The report highlights the competitive scenario of the Global Prescription Drug Market to know the competition at the national and global level. The market experts also provided an overview of each major player in the global Prescription Drugs Market, taking into account key aspects such as business areas, production, and product portfolio. Further, the companies in the report are studied on the basis of key factors such as company size, market share, market growth, revenue, production volume, and profit.

The main players covered by the prescription drugs markets:

  • Pfizer
  • rock
  • Sanofi
  • Johnson & johnson
  • Merck & Co. (msd)
  • Novartis
  • Abbvie
  • Gilead Sciences
  • Glaxosmithkline (gsk)
  • Amgen
  • Astrazeneca
  • Bristol-myers Squibb
  • Eli lilly
  • Suits you
  • Bayer
  • Novo Nordisk
  • Allergan
  • Takeda
  • Boehringer Ingelheim
  • Takeda

Prescription Drugs Market Breakdown by Type:

Prescription Drugs Market Split By Application:

The Prescription Drug Market report has been separated into distinct categories such as product type, application, end user, and region. Each segment is rated on the basis of CAGR, share and growth potential. In the regional analysis, the report highlights the potential region, which is expected to generate opportunities in the global Prescription Drug Market in the coming years. This segmental analysis will surely prove to be a useful tool for the readers, stakeholders and market players to get a complete picture of the global Prescription Drugs Market and its growth potential in the coming years.

Get | Discount on purchasing this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=202717

Scope of Prescription Drugs Market Report

Report attribute Details
Market size available for years 2021 – 2028
Reference year considered 2021
Historical data 2015 – 2019
Forecast period 2021 – 2028
Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
Covered segments Types, applications, end users, etc.
Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Scope of customization Free customization of reports (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
Price and purchase options Take advantage of custom shopping options to meet your exact research needs. Explore purchasing options

Regional Prescription Drugs Market Analysis can be represented as follows:

Each regional Prescription Drug industry is carefully studied to understand its current and future growth scenarios. It helps the players to strengthen their position. Use market research to get a better perspective and understanding of the market and target audience and to ensure you stay ahead of the competition.

Based on geography, the global prescription drug market has segmented as follows:

    • North America includes the United States, Canada and Mexico
    • Europe includes Germany, France, UK, Italy, Spain
    • South America includes Colombia, Argentina, Nigeria and Chile
    • Asia-Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

Key questions answered in the report:

  • What is the growth potential of the prescription drug markets?
  • Which product segment will take the lion’s share?
  • Which regional market will emerge as a precursor in the years to come?
  • Which application segment will grow at a sustained rate?
  • What are the growth opportunities that could emerge in the lock washer industry in the years to come?
  • What are the main challenges that the global prescription drug markets could face in the future?
  • Who are the leading companies in the global prescription drug market?
  • What are the main trends that are positively impacting the growth of the market?
  • What are the growth strategies considered by the players to maintain their grip on the global Prescription Drugs market?

For more information or a query or a personalization before purchasing, visit @ https://www.marketresearchintellect.com/product/prescription-drugs-market-size-and-forecast/

Visualize Prescription Drug Market Using Verified Market Intelligence: –

Verified Market Intelligence is our BI platform for telling the story of this market. VMI provides in-depth predictive trends and accurate insight into over 20,000 emerging and niche markets to help you make key revenue impact decisions for a bright future. VMI provides a comprehensive overview and global competitive landscape by regions, countries and segments, as well as as key players in your market. Present your market reports and findings with built-in presentation capabilities, delivering over 70% of time and resources to investors, sales and marketing, R&D and product development. VMI supports data delivery in interactive Excel and PDF formats and provides over 15 key market indicators for your market.

Visualize the Prescription Drug Market Using VMI @ https: //www.marketresearchintellect.com/mri-intelligence/

The study thoroughly explores the profiles of the major market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the production, revenue, market share and growth rate of the Prescription Drugs market for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and. applications. Historical prescription drug distribution data from 2016 to 2020 and forecast to 2021-2029.

About us: Market research intelligence

Market Research Intellect provides syndicated and personalized research reports to clients from various industries and organizations in addition to the goal of providing personalized and in-depth research studies. range of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. Etc. Our research studies help our clients make more data-driven decisions, admit push predictions, grossly capitalize on opportunities, and maximize efficiency by acting as their criminal belt to adopt accurate mention and essential without compromise. clients, we have provided expertly-behaved affirmation research facilities to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

Contact us:
Mr. Edwyne Fernandes
United States: +1 (650) -781-480
UK: +44 (753) -715-0008
APAC: +61 (488) -85-9400
US Toll Free: +1 (800) -782-1768

Website: –https://www.marketresearchintellect.com/

read more
Medical supplies

Dominican Red Cross donates medical supplies to the National COVID-19 Vaccination Unit

The Dominican Red Cross COVID-19 response program donated medical supplies worth twenty thousand Eastern Caribbean dollars ($ 20,000 XCD) to the National COVID-19 Vaccination Unit. This is to further support the on-going vaccination / immunization program focused on preventing and limiting the further spread of the coronavirus.

The National COVID-19 Vaccination Unit Coordinator, Dr Keevian Burnette, thanked the Dominican Red Cross for contributing items that included syringes, bandages, alcohol prep swabs, among others. Dr Burnette highlighted the enormous support the Ministry of Health has received to date from the Dominican Red Cross since the onset of the disease. He noted that partners and stakeholders like the Dominican Red Cross are making the work of the immunization unit much easier throughout the pandemic.

Speaking on behalf of the Dominican Red Cross, President Reginald Winston noted that since the onset of COVID, the Dominican Red Cross has taken its auxiliary role to the government seriously and has provided support, a education, awareness, relief supplies to help humanity throughout this unprecedented pandemic.

The donation was made at the Dominican Red Cross National Headquarters office in Goodwill on Tuesday 28e December 2021.

read more
Medical products

FDA clears two oral drugs for COVID-19 – Medical Products Supply Chain Weekly Review – Food, Drugs, Healthcare, Life Sciences

United States: FDA clears two oral drugs for COVID-19 – Medical products supply chain review of the week

To print this article, simply register or connect to Mondaq.com.

Last week, the FDA cleared oral antivirals from Pfizer and Merck for the treatment of COVID-19. The Biden-Harris administration released the trucking action plan. The CDC approved the ACIP preference recommendation for the Pfizer-BioNTech and Moderna vaccine boosts. The new recommended Tris vaccine buffer leads to greater stability and does not require dilution. Please see details of these and other supply chain developments below:

  • On December 15, the FDA approved Eagle Pharmaceuticals’ Abbreviated New Drug Application (ANDA) for injection of vasopressin (20 units / ml in multidose vials), a product that has grown in demand during the COVID-pandemic. 19. The FDA said that this approval, the first approval from an ANDA for this product, represents the agency’s commitment “to facilitate access to medical products to help meet the critical needs of the American public.”
  • On December 16, the Authority released its Trucking Action Plan to help reduce supply chain disruption as part of initiatives promoted by the Chain Disruption Task Force. supply. Globally, the plan aims to implement measures to reduce barriers to the issuance of commercial driver’s licenses (CDLs); accelerate the learning of trucking; recruit veterans, especially those with previous trucking experience, into the industry; and schedule listening sessions with the current workforce to implement improvement strategies. In order to promote immediate implementation, the plan also includes specific actions for 30, 60 and 90 days to implement the objectives of the plan.
  • On December 16, the FDA approved the use of Tris buffer for the manufacture of Pfizer-BioNTech’s Comirnaty COVID-19 vaccine. This new formulation offers two key advantages to vaccinators: (1) it increases the stability of the vaccine longer at refrigerated temperatures; and (2) it does not require dilution by the supplier before use.
  • On December 16, the CDC approved the Advisory Committee on Immunization Practices (ACIP) recommendations that the Pfizer-BioNTech and Moderna vaccines are preferred for booster use over the Johnson & Johnson vaccine. ACIP met earlier today and based its decision on data including a review of efficacy and adverse events.
  • On December 17, the FDA announced that it was considering a program that would impose sterilization changes to the master file pilot program for 510 (k) approved medical devices. The change applies to the established Category B or to new sterilization methods. In addition to manufacturers in the innovation challenge, current 510 (k) holders can also participate in two previous programs where the FDA (1) has challenged manufacturers to develop new ways to develop alternatives to the ethylene oxide; and (2) reduce emissions of ethylene oxide. If changes are made to sterilization methods when ethylene oxide is used, participants can now refer to their master files instead of submitting a new 510 (k).
  • On December 20, Moderna announced that it was continuing to advance clinical trials to develop an omicron-specific vaccine for use as a booster. He also noted that the antibodies from his 50mcg and 100mcg booster doses demonstrated a 37- and 83-fold increase in antibody levels. Clinical trials of vaccines targeting both omicron and delta are underway.
  • On December 21, the Center for Devices and Radiological Health (CDRH) released a plan for how the CDRH intends to manage reviewer workload in 2022 based on the increase in the total number of submissions. In 2021, the CDRH saw an increase in medical device submissions for approval through the traditional processes, namely the PMA, 510 (k) and Q-sub processes, which it addressed through the implementation of new approaches to review, including triage of cases, reallocation of staff and resources to COVID-19 products, use of contractors and overtime. Despite these approaches, some issues related to meeting review deadlines still need to be addressed. For devices other than in vitro diagnostics, the CDRH expects to be able to comply with the review deadlines of the Medical Device User Fee Agreement (MDUFA) in 2022 despite the influx of medical products subject to review. For in vitro diagnostic products, the CDRH will also try to meet the deadlines promised by the MDUFA. Non-COVID products that were not prioritized during the pandemic will require extended review times. In addition, the pre-submission request program will be reinstated as of January 1, 2022.
  • On December 22, the FDA cleared Pfizer’s oral antiviral drug, Paxlovid, for the treatment of mild to moderate COVID-19 in adults and children 12 years of age or older (weighing 40 kg or more). This is the first oral antiviral treatment for COVID-19 to receive emergency use authorization. The clearance was based on data from the EPIC-HR trial, which demonstrated that Paxlovid significantly reduced hospitalizations and deaths from all causes in the study population compared to those randomized to receive a placebo. Paxlovid is a combination of nirmatrelvir and ritonavir – the former inhibits the replication of SARS-CoV-2 and the latter slows down the breakdown of nirmatrelvir in the body. The FDA will continue to monitor clinical trial data for the safety and effectiveness of the drug.
  • On December 23, the FDA cleared Merck’s oral antiviral drug, molnupiravir, for the treatment of mild to moderate COVID-19 in adults at high risk of progression to severe COVID-19 and for whom options for Alternative treatment to COVID-19 is not available. accessible or clinically appropriate.

The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

POPULAR ARTICLES ON: Food, Medicines, Health Care, Life Sciences of the United States

read more
Prescription drugs

Crackdown on the illegal sale of prescription drugs

Police have launched a crackdown on the illegal sale of “prescription drugs” by pharmacies across the state.

Acting on the instructions of the Director General of Police C. Sylendra Babu, special teams from the Narcotics Intelligence Bureau CID as well as officials from the Department of Food Safety and Drug Administration carried out surprise checks in pharmacies in several districts. The aim was to reduce the sale of these drugs without a proper prescription, especially to students and young people.

According to Mahesh Kumar Aggarwal, ADGP, Crime, action has been taken against some pharmacies in the districts of Chengalpattu, Tiruvannamalai, Thanjavur, Salem, Vellore and Tirupattur. Police and the Department of Food Safety and Drug Administration had warned pharmacy owners not to sell over-the-counter “prescription drugs”. Surprise checks would continue, he said. Mr. Aggarwal called on the public to pass on any information about the illegal sale of controlled drugs by calling the hotline 10581 or sending a message via WhatsApp to 949810581. The public can email this contribution to spnibcid @ gmail. com.

In a separate operation, the police conducted a special campaign in all neighborhoods against the sale of narcotics and psychotropic substances. During the operation, over 2,000 kg of ganja and 21 kg of heroin worth approximately 23 crore were seized and 838 accused persons arrested. Some of these suspects had sold contraband to drug addicts. The move follows instructions from Chief Minister Deputy Stalin, who briefed the Assembly on the matter and told officials at a recent meeting that strict measures should be taken to curb the sale of drugs such as ganja near educational institutions, the sources said.

Intervention force

Earlier this week, the national meeting of the Narco Coordination Center Apex Level Committee (NCORD) described drug abuse as a major national security threat that could be addressed with comprehensive coordination between central agencies. and drug control states. The meeting, which was attended by senior police officers from across the country, was asked to form a dedicated anti-narcotics task force, the sources added.

read more
Medical supplies

EcoMedSupply: A Leading Provider Of Environmentally Friendly Medical Supplies, Office Supplies And Foodservice In The United States

EcoMedSupply continues its mission of providing top-notch green supplies that offer high level protection and meet ASTM Level 3 mask standards with one of the highest filtrations on the market.

Protecting the environment is not the business of environmental specialists alone. All hands should be on deck to ensure that the land and its contents are preserved for continued survival and existence. There is no gain in saying that balance is getting harder and harder to achieve, but with organizations like EcoMedSupply, it is now possible to conserve land and make it suitable for habitation.

EcoMedSupply has provided environmentally friendly products, all meeting ASTM standards for high level protection. Founded by Barbara Inwald, MD, EcoMedSupply prides itself on its ability to provide customers with a wide selection of supplies while making them environmentally friendly. While other companies compromise on quality or skimp on catalog size, EcoMedSupply offers thousands of products from hundreds of vendors in an easy-to-use centralized marketplace designed for start-to-finish simplicity and convenience.

EcoMedSupply’s categories of green supplies include medical, dental, personal and skin, veterinary and pet care, office and food. Within the medical supplies category, there are exam room supplies, PPE and staff clothing, office and home care, bed pans and incontinence care, and EMS supplies. , among other articles. The dental supplies category offers supplies for all parts of the dental office, including toothbrushes and floss, HVEs, saliva ejectors, prophylaxis angles, micro-applicators, syringe tips A / W, arc trays, impression syringes, and examination room paper products.

Spas, wellness centers, and homes in need of green skin care supplies will find the best products in EcoMedSupply’s personal and skin care supplies category. Veterinarians and pets are also included in EcoMedSupply’s scope to provide environmentally friendly supplies. EcoMedSupply is undoubtedly leading the way in the conservation of natural life with its categories of food and office supplies.

In addition to this, EcoMedSupply offers an informative section on its website, educating visitors about the environmental impact on healthcare and why concerted efforts should be made to ensure that only environmentally friendly products are made and used around the world today. To join the Ensuring the Earth is Safe for Home and for Posterity course, please visit www.ecomedsupply.com and purchase one of the very affordable and environmentally friendly products available.

Media contact
Company Name: EcoMedSupply
Contact: Barbara inwald
E-mail: Send an email
Call: 415-250-5393
Country: United States
Website: http://www.ecomedsupply.com/

read more
Generic drugs

Generic drugs provide information to doctors, so why is Health Canada promoting pharmaceutical brand names?

Generic drug names are often long, but they can tell doctors what type of drug it is and how it works. But it is the brand names that appear first and most prominently in Health Canada documents.

Brand names are widely used when we want to refer to a specific product – an Apple computer, a Tesla car. Sometimes brand names are used so widely that they take over – we ask for a Kleenex instead of a tissue.

Drugs have two names. The brand name is the one chosen by the company that manufactures it and that company is the only one authorized to use the name. (The name proposed by the company is being reviewed by Health Canada.) Brand names are almost always short and catchy so that physicians will remember them.

Generic names are assigned globally by the World Health Organization in collaboration with national naming authorities. These names are often long, but part of the reason for this is that they tell doctors about the pharmacological properties and / or chemical structure of the drug.

The generic name of the US $ 2 million per patient new drug for spinal muscular atrophy is onasemnogene abeparvovec. The brand name is Zolgensma. Which one will physicians (and patients) retain and use? The answer is obvious.

One of the associate editors of the Canadian Medical Association Journal notes that “some brand names are created to be reassuring or promising – so-called ‘benefit-oriented’ names such as Paxil, Celebrex, and Gluconorm – while they should in fact be prescribed with great care and taking into account the potential effects of the drug on each patient.

Is using brand names the right way to talk about prescription drugs? Apparently, Health Canada thinks so. Do you want information on safety issues with a medicine? On the Canadian recall site, you will see the brand name in CAPITALS and the generic name in lower case and in parentheses.

Want to see if there is a shortage of the drug your doctor just prescribed for you? Go to Drug Shortages Canada and you will find the brand names of the drugs, again in all caps.

If you want to know why Health Canada approved a particular drug, the Basis of Approval Summary document will help you understand. But again, the brand name is the most important, and again it’s in all caps.

What’s in a name?

In medical school, students learn to use generic names. Medical journals require authors to use generic names in the articles they write. Does the name used by doctors matter? The answer is yes.

When Australian anesthesiologists and doctors trained to be anesthesiologists at two university hospitals were given the brand names of the drugs, they could only correctly identify the therapeutic group from which the drug came in just over half of the cases. Without knowing which therapeutic group the drug was from, doctors could have accidentally used another drug from the same group or they could have used the drug incorrectly.

The more money doctors received from drug companies in the form of meals, travel arrangements, and property royalties, the less likely they were to prescribe by generic name. Seeing pharmaceutical company sales representatives more frequently is associated with increased prescriptions for brand name products, resulting in more expensive prescriptions. Sales representatives also typically omit important information about the safety of the drugs they are promoting. Therefore, besides more expensive prescriptions, they can also be more likely to harm patients.

Brand names, drug regulation (the domain of Health Canada) and drug promotion came together particularly blatantly in the case of buprenorphine-naloxone, the brand name Suboxone, an opioid drug used to treat addiction. opioids.

Even though generic formulations of the drug have been available in Canada since 2013 (and even earlier in the United States), the drug is widely referred to by its brand name, including in the media, by policymakers, and by physicians.

Brand education

This happened in particular through the promotion of an “educational” program developed and implemented by Indivior, the company which owns the rights to Suboxone. In some provinces, completing this branded program is a prerequisite for prescribing buprenorphine-naloxone. The same strategy was used for a related injectable form of buprenorphine, also owned by Indivior.

This use of the branded program is the case even though there are already some very good accredited, non-industry educational programs to teach proper opioid addiction care and prescriptions to doctors, nurses and pharmacists.

The inclusion of the brand name in the title of this program is against recommended practices and accreditation standards for Canadian medical education programs.

Yet the brand-name program is fully endorsed by Health Canada through that agency’s review and approval of the Suboxone Product Monograph. This document, which describes the nature of the drug and its approved uses in Canada, includes a description of the requirement to participate in the branded “training program”.

As has been documented in the United States, Indivior and its parent company Reckitt Benckiser have engaged in various unscrupulous practices to promote their multibillion-dollar line of buprenorphine products – ultimately paying some of the largest fines in the world. pharmaceutical history of the United States. From this perspective, a branded “educational” program appears to be yet another vehicle for brand promotion, and one in which Health Canada is directly involved.

When doctors use brand names, they may be less knowledgeable about the medications they are prescribing, their prescriptions cost more, and patients may be more likely to suffer from side effects. When Health Canada prioritizes brand names over generic names, it is actively contributing to all of these issues.

Health Canada should know better and do better.

In 2018-2021, Joel Lexchin received payments for writing a dissertation in a drug side effects action for Michael F. Smith, lawyer, and a second dissertation on the role of promotion in generating orders for Goodmans LLP and Canadian Institutes of Health Research for a presentation at a workshop on conflicts of interest in clinical practice guidelines. He is currently a member of research groups that receive funding from the Canadian Institutes of Health Research and the Australian National Health and Medical Research Council. He is a member of the Foundation Board of Health Action International and the Board of Canadian Doctors for Medicare. It receives royalties from the University of Toronto Press and James Lorimer & Co. Ltd. for the books he wrote.

Abhimanyu Sud has received funding or has been consulted by the Canadian Institutes of Health Research, Health Canada, the Association of Faculties of Medicine of Canada, the University of Toronto, the Center for Effective Practice and the Mississauga-Halton Local Health Integration Network for research and medical education related to opioid use and drug policy.

read more
Generic drugs

Generic drugs provide information to physicians, so why is Health Canada promoting pharmaceutical brand names?

Generic drug names are often long, but they can tell doctors what kind of drug it is and how it works. But it’s the brand names that appear first and most prominently in Health Canada documents.

Brand names are widely used when we want to refer to a specific product – an Apple computer, a Tesla car. Sometimes brand names are so widely used that they take over – we ask for a Kleenex instead of a tissue.

Medicines have two names. The brand name is the one chosen by the company that manufactures it and this company is the only one authorized to use the name. (The company’s proposed name is reviewed by Health Canada.) Brand names are almost always short and catchy so doctors will remember them.

Generic names are assigned globally by the World Health Organization in conjunction with national naming authorities. These names are often long, but part of the reason for their length is that they inform doctors about the pharmacological property and/or chemical structure of the drug.

The generic name of the US$2 million per patient new drug for spinal muscular atrophy is onasemnogene abeparvovec. The brand name is Zolgensma. Which one will doctors (and patients) remember and use? The answer is obvious.

One of the associate editors of the Canadian Medical Association Journal points out that “some brand names are created to be reassuring or promising — so-called ‘benefit-based’ names like Paxil, Celebrex and Gluconorm — whereas they actually need to be prescribed with great care and taking into account the potential effects of the drug on each patient.

Is using brand names the right way to talk about prescription drugs? Apparently Health Canada thinks so. Would you like information on the safety issues of a medicine? On the Canada recall site, you will see the brand name in UPPERCASE and the generic name in lowercase and in parentheses.

Want to see if there’s a shortage of the drug your doctor just wrote you a prescription for? Go to Drug Shortages in Canada and you will find the brand names of the drugs, again in all caps.

If you want to know why Health Canada approved a particular drug, the Summary of Reasons for Approval document will help you understand. But again, the brand name is the most important, and again it’s in capitals.

What’s in a name?

In medical school, students learn to use generic names. Medical journals ask authors to use generic names in the articles they write. Does the name used by doctors matter? The answer is yes.

When Australian anesthetists and physicians training to become anesthetists at two teaching hospitals were given the brand names of the drugs, they were only able to correctly identify the therapeutic group the drug came from in just over half of the case. Without knowing which therapeutic group the medicine came from, doctors might have accidentally used another medicine from the same group or used the medicine incorrectly.

The more money physicians received from drug companies in the form of meals, travel, and property royalties, the less likely they were to prescribe by generic name. Seeing pharmaceutical company sales representatives more frequently is associated with more prescriptions for brand name drugs, which translates into more expensive prescriptions. Sales reps also typically leave out important safety information about the drugs they promote, so in addition to prescriptions costing more, they may also be more likely to harm patients.

Brand names, drug regulation (the domain of Health Canada) and pharmaceutical promotion have come together in a particularly blatant way in the case of buprenorphine-naloxone, brand name Suboxone – an opioid drug used to treat drug addiction. opioids.

Even though generic formulations of the drug have been available in Canada since 2013 (and even earlier in the United States), the drug is widely referred to by its brand name, including in the media, by policymakers, and by doctors.

brand education

Part of this happened through the promotion of an “educational” program developed and delivered by Indivior, the company that owns the rights to Suboxone. In some provinces, following this branded program is a prerequisite for being able to prescribe buprenorphine-naloxone. The same strategy was executed for a related injectable form of buprenorphine, also owned by Indivior.

This use of the branded program is the case even though there are already very good, accredited, non-industry educational programs to teach proper opioid addiction care and prescribing to physicians, nurses, and pharmacists.

The inclusion of the brand name in the title of this program is against recommended practices and standards for accreditation of medical education programs in Canada.

Yet, the branded program is fully sanctioned by Health Canada through that body’s review and approval of the Suboxone product monograph. This document, which describes the nature of the drug and its approved uses in Canada, includes a description of the requirement for participation in the branded “training program”.

As documented in the United States, Indivior and its parent company Reckitt Benckiser engaged in a variety of unscrupulous practices to promote their multi-billion dollar line of buprenorphine products – ultimately paying some of the largest fines in the industry. American pharmaceutical history. From this perspective, a branded “educational” program seems to be one more vehicle for promoting a brand, in which Health Canada is directly complicit.

When doctors use brand names, they may be less knowledgeable about the drugs they prescribe, their prescriptions cost more, and patients may be more likely to experience side effects. When Health Canada prioritizes brand names over generic names, it is actively contributing to all of these issues.

Health Canada should know better and must do better.

In 2018-2021, Joel Lexchin received payments for writing a memoir in a drug side effects action for attorney Michael F. Smith and a second memoir on the role of promotion in the generation of orders for Goodmans LLP and Canadian Institutes of Health Research for a presentation at a workshop on conflict of interest in clinical practice guidelines. He is currently a member of research groups that receive funding from the Canadian Institutes of Health Research and the Australian National Health and Medical Research Council. He is a member of the Foundation Board of Health Action International and of the Council of Canadian Physicians for Medicare. He receives royalties from the University of Toronto Press and James Lorimer & Co. Ltd. for the books he wrote.

Abhimanyu Sud has received funding from or consulted with the Canadian Institutes of Health Research, Health Canada, the Association of Faculties of Medicine of Canada, the University of Toronto, the Center for Effective Practice, and the Mississauga-Halton Local Health Integration Network for research and medical education regarding opioid use and drug policy.

read more
Medical products

FDA Approves Two Oral COVID-19 Drugs – Medical Products Supply Chain Weekly Review | Alston & Bird

Last week, the FDA cleared oral antivirals from Pfizer and Merck for the treatment of COVID-19. The Biden-Harris administration released the trucking action plan. The CDC approved the ACIP preference recommendation for the Pfizer-BioNTech and Moderna vaccine boosts. The new recommended Tris vaccine buffer leads to greater stability and does not require dilution. Please see details of these and other supply chain developments below:

  • On December 15, the FDA approved Eagle Pharmaceuticals’ Abbreviated New Drug Application (ANDA) for injection of vasopressin (20 units / ml in multidose vials), a product that has grown in demand during the COVID-pandemic. 19. The FDA said that this approval – the first approval from an ANDA for this product – represents the agency’s commitment “to facilitate access to medical products to help meet the critical needs of the American public.”
  • On December 16, the Authority released its Trucking Action Plan to help reduce supply chain disruption as part of initiatives encouraged by the Chain Disruption Task Force. supply. Globally, the plan aims to implement measures to reduce barriers to the issuance of commercial driver’s licenses (CDLs); accelerate the learning of trucking; recruit veterans, especially those with previous trucking experience, into the industry; and schedule listening sessions with the current workforce to implement improvement strategies. In order to promote immediate implementation, the plan also includes specific actions for 30, 60 and 90 days to implement the objectives of the plan.
  • On December 16, the FDA approved the use of Tris buffer for the manufacture of Pfizer-BioNTech’s Comirnaty COVID-19 vaccine. This new formulation offers two key advantages to vaccinators: (1) it increases the stability of the vaccine longer at refrigerated temperatures; and (2) it does not require dilution by the supplier before use.
  • On December 16, the CDC approved the Advisory Committee on Immunization Practices (ACIP) recommendations that the Pfizer-BioNTech and Moderna vaccines are preferred for booster use over the Johnson & Johnson vaccine. ACIP met earlier today and based its decision on data including a review of efficacy and adverse events.
  • On December 17, the FDA announced that it was considering a program that would impose sterilization changes to the master file pilot program for 510 (k) approved medical devices. The change applies to the established Category B or to new sterilization methods. In addition to manufacturers in the innovation challenge, current 510 (k) holders can also participate in two previous programs where the FDA (1) has challenged manufacturers to develop new ways to develop alternatives to it. ethylene oxide; and (2) reduce emissions of ethylene oxide. If changes are made to sterilization methods when ethylene oxide is used, participants can now refer to their master files instead of submitting a new 510 (k).
  • On December 20, Moderna announced that it was continuing to advance clinical trials to develop an omicron-specific vaccine for use as a booster. He also noted that the antibodies from his 50mcg and 100mcg booster doses demonstrated a 37- and 83-fold increase in antibody levels. Clinical trials of vaccines targeting both omicron and delta are underway.
  • On December 21, the Center for Devices and Radiological Health (CDRH) released a plan for how the CDRH intends to manage reviewer workload in 2022 based on the increase in the total number of submissions. In 2021, the CDRH saw an increase in medical device submissions for approval through the traditional processes, namely the PMA, 510 (k) and Q-sub processes, which it addressed through the implementation of new approaches to review, including triage of cases, reallocation of staff and resources to COVID-19 products, use of contractors and overtime. Despite these approaches, some issues related to meeting review deadlines still need to be resolved. For devices other than in vitro diagnostics, the CDRH expects to be able to meet the review deadlines of the Medical Device User Fee Agreement (MDUFA) in 2022 despite the influx of medical products subject to review. For in vitro diagnostic products, the CDRH will also try to meet the deadlines promised by the MDUFA. Non-COVID products that were not prioritized during the pandemic will require extended review times. In addition, the pre-submission request program will be reinstated as of January 1, 2022.
  • On December 22, the FDA cleared Pfizer’s oral antiviral drug, Paxlovid, for the treatment of mild to moderate COVID-19 in adults and children 12 years of age or older (weighing 40 kg or more). This is the first oral antiviral treatment for COVID-19 to receive emergency use authorization. The clearance was based on data from the EPIC-HR trial, which demonstrated that Paxlovid significantly reduced hospitalizations and deaths from any cause in the study population compared to those randomized to receive a placebo. Paxlovid is a combination of nirmatrelvir and ritonavir – the former inhibits the replication of SARS-CoV-2 and the latter slows down the breakdown of nirmatrelvir in the body. The FDA will continue to monitor clinical trial data for the safety and effectiveness of the drug.
  • On December 23, the FDA cleared Merck’s oral antiviral drug, molnupiravir, for the treatment of mild to moderate COVID-19 in adults at high risk of progression to severe COVID-19 and for whom options for Alternative treatment to COVID-19 is not available. accessible or clinically appropriate.

[View source.]

read more
Prescription drugs

Florida to become the first state to import prescription drugs from Canada

Plans to import cheaper prescription drugs from Canada have been in the works for years. In Florida, it could finally happen sooner than many realize – perhaps as early as early next year.

Florida Health Care Administration Secretary Simone Marsiller recently told a state Senate panel, “Hopefully we can start importing in the first quarter of the new year.

The fact that, while they differ in everything else, President Joe Biden and Governor Ron DeSantis both support her.

“If you have drugs in Canada, the same drug costs 25 percent of what it costs here. We want Floridians to be able to share those discounts,” DeSantis said.

A RAND study looked at drug prices in nearly 40 countries and found that the United States pays more than all prescription drugs. Average prices have risen by about 250% in the United States or, as President Biden recently noted, “about two to three times what other countries pay.”

In the United States, insurance companies cover most of the cost of drugs for those who are insured. But those without coverage and those with insurance that doesn’t cover their particular medications burn themselves or go without.

In Canada, prescription drugs are much cheaper because the Canadian government regulates and controls the prices. So the idea is to help Americans take advantage of Canada’s price controls.

As you might expect, the pharmaceutical lobby opposes plans to import prescription drugs from Canada. He ran advertisements questioning the safety of using drugs imported from other countries – an advertisement even stating: “Too many have already died from counterfeit drugs; are you willing to take that risk? “

PREVIOUS: Advertising campaign claims imported drugs are risky for Floridians

But Governor Ron DeSantis says we can trust Canada – and Congress agrees. He passed a law allowing commercial imports of drugs from Canada in 2003. Sixteen years later, Florida was one of the first states to begin the process.

The state has spent the past two years putting the system in place, which the governor says will keep it safe.

“This program only applies if we show that we are providing drugs that are safe and cheaper than what we already have,” said Governor DeSantis.

The final step is FDA clearance, and President Biden has already ordered the FDA to get to work. As soon as the FDA gives the green light, Florida plans to take action.

PREVIOUS: Florida drug import plan moves forward

Life Science Logistics in Lakeland is ready at this time. Its warehouses would start filling up with boxes and bottles of pills – all prescription drugs from Canada.

“We’re ready to start importing in 90 days,” a company spokesperson told FOX 13.

The state has not defined or announced certain details, such as which drugs will come first. State officials have suggested they could start with drugs to treat diabetes, hepatitis, COPD and / or HIV / AIDS.

They will likely start with a small number of drugs for those with Medicaid, then for others with public insurance. Further expansion would be based on the success of the program as well as demand.

There are some wrinkles in the plane that need to be addressed. The pharmaceutical industry is challenging it in court. And supplies can also be a problem, as Canada cannot supply its own citizens while having enough for the United States, or even all of Florida, for that matter. Shipments should be considered “surplus” or “surplus” in the Canadian market.

But after years of planning, Florida could overcome these hurdles in 2022, triggering big changes in where we get our drugs and how much we pay for them.

read more
Prescription drugs

Counterfeit prescription drugs and illicit cigarettes worth hundreds of thousands of pounds seized in Orford raid

TWO men have been arrested after police seized hundreds of thousands of pounds of counterfeit prescription drugs and illicit cigarettes following a raid in Orford, Warrington.

Over the past several months, agents from the Warrington Problem-Solving Team have conducted a detailed investigation into the illegal supply of prescription drugs in the town.

On Tuesday, December 21, the team conducted a warrant at an address in Orford where they recovered thousands of counterfeit prescription drugs, around £ 200,000 of counterfeit cigarettes and tobacco and a large amount of stolen wine and spirits .

Two local men, aged 67 and 31, were also arrested at the address on suspicion of money laundering and receiving stolen property.

The couple have since been released under investigation pending further investigation.

Sergeant Anthony Sullivan of the Warrington Problem Solving Team said: “This warrant is part of our ongoing investigation into the supply of illegal drugs.

“Illegal drugs have no place in our city; they are ruining the lives of some of the most vulnerable people in our community, while lining the pockets of shameless criminals.

“I want to reassure the public that we are doing everything we can to crack down on this type of activity.

“However, we cannot do our job without the help of the public and cannot repeat the message enough that you are essential in helping your community by reporting illegal activity to us.

“If anyone has any information about illegal drug activity or any other criminal activity taking place in your community, they should report it to Cheshire Police on 101 or www.cheshire.police.uk/tua .

“Information may also be reported anonymously, via Crimestoppers, on 0800 555 111.”

read more
Prescription drugs

The future of the safe harbor for prescription drugs remains uncertain

In November 2020, four months after the Trump administration issued a series of executive orders reiterating its policy goals on reducing costs for consumers of prescription drugs and leading the Department of Health and Human Services, Office of the Inspector General (“HHS-OIG”) to implement these policy objectives, the HHS-OIG has issued a Final rule to amend certain provisions of the Safe Harbor regulation under the Federal Anti-Recoil Act (“AKS”). The final rule included three key provisions:

  1. Removal Safe Harbor protection for manufacturer discounts paid directly or indirectly through a Pharmacy Benefits Manager (“PBM”) to Medicare Part D or Medicare Advantage plans (the “Discount Rule”). “);
  2. Creation of a new safe harbor to protect point-of-sale (“POS”) price reductions paid by manufacturers to Medicare Part D plans, Medicare Advantage plans and Medicaid managed care organizations (“MCO”); and
  3. Creation of a new safe harbor to protect the fair market value (FMV) service fees paid to PBMs by manufacturers.

The final rule imposed an effective date of January 1, 2022 for the discount rule. However, in January 2021, two months after the final rule was issued and in a lawsuit by the Pharmaceutical Care Management Association challenging the surrender rule, the Biden administration agreed to postpone the entry date. in force of the discount rule on January 1, 2023, as reflected in a Order by the United States District Court for the District of Columbia.

In the meantime, however, Congress passed the Law on investment in infrastructure and employment (the “Infrastructure Act”). This law, signed by President Biden on November 15, 2021, further delayed the implementation of the discount rule until January 2026. Thus, the rule, which many believed would be removed as part of the payment of the cost of the infrastructure bill, was still alive, if only delayed until the middle of the next presidential term.

Then, on November 19, 2021, the House of Representatives adopted the Rebuild Better Act (“BBBA”), which included the last nail in the coffin of the ruler. Section 139301 of this bill stated that the HHS-OIG “shall not implement, administer or enforce” any of the provisions of the rule. This was the total repeal that had been provided for in the previous law.

The bill went to the Senate before Thanksgiving and was to go through a reconciliation process that is exempt from Senate filibuster rules and would only have required all 50 Democratic and Independent Senators to vote for, the Deputy Speaker Kamala Harris playing the tiebreaker role. 51st vote in favor of the bill. However, Senator Joe Manchin (D – W. Va.) Recently announced his opposition to the bill, and his vote could prevent the bill from being passed. If the BBBA is not passed by the Senate, its ban on implementing the final rule will fail with it, and unless any further action is taken, the discount rule will take effect in January 2026.

As a result, it is not clear until the Senate took action in January whether PBMs, MCOs, Part D plans and Medicare Advantage plans will need to worry about these changes to the anti-rollback provisions. . If the Senate does not pass the bill, then all of these entities should begin reviewing their policies and procedures over the next four years in preparation for the rule coming into force.

Reed Smith will continue to monitor developments related to the discount rule and its impact on the industry.

read more
Medical supplies

Fidelity Securities Limited donates medical supplies to police hospital

Fidelity Securities Limited, a subsidiary of Fidelity Bank Ghana Limited, donated medical supplies to the pediatric ward of the Ghana Police Hospital in Accra.

The supplies, including a CPAP machine, infuser, x-ray viewer, pulse oximeter, digital thermometer, pediatric ambubag, industrial nebulizer, oxygen concentrator (5L) and oxygen flow meter will help to provide health care to the children on the unit.

Presenting the articles at Ghana Police Hospital, Edward Opare-Donkor, Board Member of Fidelity Securities Limited, said: “Fidelity Securities Limited is more than grateful for being able to fulfill its civic duty in helping to save the lives of children across the country who visit the facility. Indeed, we are committed to supporting the government in providing the best health care to the people of Ghana. “

Mr. Opare-Donkor noted that this was only the beginning of Fidelity Securities Limited’s relationship with the Ghana Police Hospital and he encouraged the Ghana Police Hospital to continue its selfless sacrifice to the nation.

Receiving the articles on behalf of Ghana Police Hospital, Dr Ebenezer Ewusi-Emmim, Medical Director of Ghana Police Hospital, said: “We appreciate Fidelity Securities Limited for supporting us with these valuable medical supplies at this very critical time.

“We will use these supplies wisely while encouraging them and other commercial institutions to continue to support us in delivering first-class health services to the people of this country.”

FSL’s support to the Ghana Police Hospital is a demonstration of its commitment to the general well-being of Ghanaians through its social impact initiatives.

read more
Medical supplies

COVID -19: Big Caps Micro Credit donates PPE and medical supplies to Agona Swedru municipal hospital

As the holiday season begins, many hospitals and health facilities in the central region have stepped up efforts to vaccinate and educate people about the need to minimize the spread of the COVID-19 virus.

The Central Region, for example, is seeking to reach a vaccination target of one million seven hundred thousand and health officials have stepped up efforts to ensure that the target is met.

Dr Julius Agbeeku, Acting Medical Superintendent of Agona Swedru Government Hospital, said that at a time when many seemed to have forgotten about the existence of the COVID-19 virus, there was no longer a need to step up education and strengthen immunization.

The Central region recorded its first case of COVID-19 on April 8, 2020. As of December 7, 4,907 cases have been recorded cumulatively since the start of the pandemic. 98% of recorded cases, according to the GHS, have fully recovered from COVID-19. At the last count, the total number of deaths stood at 31.

Speaking at a ceremony to receive PPE and other medical supplies worth GHG 36,000 from Big Cap Micro Credit, Dr Agbeeku called on residents to protect themselves this Christmas time.

He says: “Because we’ve seen waves upon waves, pandemic efforts seem to have waned a bit. So, for them to remember that we still need to fight this pandemic, and to help with this donation, we are eternally grateful to them.

Ag. Medical Superintendent, Agona Swedru Government Hospital, Dr Julius Agbeeku

The acting medical superintendent of the government hospital of Agona Swedru also debunked the notion of some people against vaccination. He explained that the problems some people have with vaccination were unfounded and it was necessary to dismiss such thoughts.

“We make efforts to educate and sensitize people so that they reason with us in order to be vaccinated. Some of the things they say you just don’t get the basis for.

There are so many vaccines available that we can immunize a lot of people, ”he said.

He thanked BIG CAP Micro Credit for such a donation which would help fight against the virus. Management, he says, will increase its risk communication as the waves of the pandemic keep rising.

COVID -19: Big Caps Micro Credit donates PPE and medical supplies to Agona Swedru municipal hospital

Big Cap Micro Credit CEO Firdaus Mubarak Yusif explained that the donation worth 36,000 is part of their corporate social responsibility by supporting the public in the fight against the virus.

The articles, he says, were strategic articles that will eradicate many of the problems that exist in the region. He believes that if the items are used wisely, there will be many challenges.

COVID -19: Big Caps Micro Credit donates PPE and medical supplies to Agona Swedru municipal hospital
CEO of Big Cap Micro Crédit, Firdaus Mubarak Yusif

” I protect myself ; you don’t protect yourself; you have the virus. You protect yourself; I don’t protect myself; I catch the virus. As an organization, we would contribute significantly, not only to support the fight against the COVID-19 virus, but also to address the challenges of our rural health sector.

Agona West MP Cynthia Mamle Morrison expressed her appreciation for the gesture and called on the general public and businesses to support healthcare facilities in these difficult times.

COVID -19: Big Caps Micro Credit donates PPE and medical supplies to Agona Swedru municipal hospital
MP, Agona West, Cynthia Mamle Morrison

She added that at the start of the Christmas season, many people would be left out of the celebration because they are not taken care of.

“During this Christmas season, we pray that legal entities will reach out not only to hospitals, but also to the needy, the elderly, the sick and other vulnerable groups in our society. I’m telling you that without a gift some people won’t celebrate Christmas, ”she said.

read more
Generic drugs

U.S. Generic Drugs Market, By Type, By

New York, 23 Dec. 2021 (GLOBE NEWSWIRE) — Reportlinker.com Announces Release of United States Generic Drugs Market, By Type, By Application, By Mode of Drug Delivery, By Form, By Source, By Distribution Channel, By Region, Competition, Forecast and Opportunities, 2026″ – https://www.reportlinker.com/p06192577/?utm_source=GNW

The generic drugs market in the United States was valued at USD 70.78 billion in 2020 and is expected to grow at a CAGR of 9.43% during the forecast period and may reach a market value of USD 126.74 billion. ‘by 2026. Factors such as the cost-effective nature of generic drugs and growing demand from developing economies are largely responsible for this futuristic growth estimate of the US generic drugs market over the next five years. Generic drugs do not require extensive research and development like prescription drugs and brand name drugs. Market players and research institutes are investing heavily in patented pharmaceuticals. Moreover, FDA approvals for generic drugs are not required since generic drugs contain the same composition as that of the previously patented drug and thus support the growth of the generic drug market in the United States over the next five years. . The healthcare industry in the United States, in terms of generic drugs, has gone from 80% growth in 2020 to a previous growth of 20% in 2015.
The increase in generic drug exports to developing economies like Kenya, India, etc. also justifies the growth of the US generic drug market in the next five years.
The US generic drugs market is segmented on the basis of type, drug delivery route, form, manufacturing source, application, company, and regional distribution. Based on type, the market can be divided into generics and small molecule biosimilars.

Small molecule generics are expected to register the largest market revenue shares and dominate the market segment over the next five years owing to its simpler and easier manufacturing processes. Generic drug manufacturers when producing small molecule generics are required to prove that the final product contains the same chemical compounds as the patented drug.

With similar functions and pharmacokinetic properties, the generic small molecule is accepted. Additionally, the demand for cost-effective generic drugs is expected to further support the growth of the generic drugs market in the United States over the next five years.
Based on the applications, the market can be fragmented into cardiovascular diseases, diabetes, neurology, oncology, infectious diseases and others. Cardiovascular diseases are expected to dominate the market segment while recording the highest market revenue shares over the next five years on account of the increasing cases of cardiovascular diseases in the United States.

Additionally, increased demand for treatment and extended medication protocols is driving the growth of cardiovascular disease sub-segment while sustaining the growth of the generic drug market in the United States over the next five years. Rising pharmaceutical research and development for the oncology disease is expected to drive the growth of the oncology sub-segment and drive the growth of the US generic drug market over the next five years.
Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sandoz US, Endo Pharmaceuticals Inc., Aurobindo Pharma USA, Inc., Abbott Laboratories Inc., Eli Lilly and Company, Sun Pharma Inc., Lupine Pharmaceuticals, Inc. and Zydus Pharmaceutical USA Inc. is among the major market players in the United States leading the growth of the generic drugs market.

Years considered for this report:

Historical years: 2016-2019
Reference year: 2020
Estimated year: 2021
Forecast period: 2022-2026

Goal of the study:

• To analyze the historical growth of the market size of the generic drugs market in the United States from 2016 to 2020.
• Estimate and forecast the market size of Generic Drugs Market in United States from 2021 to 2026 and the growth rate till 2026.
• To classify and forecast the U.S. Generic Drugs Market based on type, application, mode of drug delivery, form, source, distribution channel, competitive landscape, and regional distribution .
• Identify the dominant region or segment in the generic drug market in the United States.
• To identify drivers and challenges for the generic drug market in the United States.
• Examine competitive developments such as expansions, new product launches, mergers and acquisitions, etc., in the generic drug market in the United States.
• Identify and analyze the profile of the main players operating in the generic drugs market in the United States.
• Identify the key sustainable strategies adopted by market players in the generic drugs market in the United States.
The analyst conducted extensive primary and secondary research for this study. Initially, the analyst procured a list of manufacturers across the world.

Subsequently, the analyst conducted primary research surveys with the identified companies. During the interviews, the respondents were also asked about their competitors.

Using this technique, the analyst could include manufacturers that could not be identified due to secondary research limitations. The analyst looked at the manufacturers, distribution channels and presence of all major players across the globe.
The analyst calculated the size of the generic drugs market in the United States using a bottom-up approach, in which data from various end-user segments was recorded and forecasted for the coming years. The analyst obtained these values ​​from industry experts and company representatives and validated them externally by analyzing historical data of these types of products and applications to derive an appropriate overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key target audience:

• Manufacturers, suppliers, distributors and other stakeholders of generic medicines
• Government bodies such as regulators and policy makers
• Organizations, forums and alliances related to generic medicines
• Market research and consulting firms
The study is helpful in providing answers to several critical questions which are important for industry stakeholders such as manufacturers, suppliers, partners, end users etc. besides enabling them to elaborate investment strategies and to capitalize on market opportunities.

Report Scope:

In this report, the generic drugs market in the United States has been segmented into the following categories, in addition to industry trends which have also been detailed below:
• Generic drugs market in the United States, by type:
o Generic Small Molecule
o Biosimilars
• Generic drugs market in the United States, by application:
o Cardiovascular diseases
o Diabetes
o Neurology
o Oncology
o Infectious diseases
o Others
• Generic drug market in the United States, by mode of drug administration:
o Oral
o Parenteral
o Topical
o Others
• Generic drugs market in the United States, by form:
o Tablet
o Capsule
o Injection
o Others
• Generic drugs in the United States, by source:
o In-house manufacturing
o Contract manufacturing organizations
• Generic drugs market in the United States, by distribution channel:
o Retail pharmacies
o Online pharmacies
o Hospital pharmacies
o Others
• Generic drugs market in the United States, by region:
o South
o Midwest
o West
o Northeast

Competitive landscape

Company Profiles: Detailed analysis of the major companies present in the global generic drugs market.

Customizations available:

With the market data provided, we offer customizations based on a company’s specific needs. The following customization options are available for the report:

Company information

• Detailed analysis and profiling of other market players (up to five).
Read the full report: https://www.reportlinker.com/p06192577/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________


        
read more
Medical products

Which medical products are at the top of Amazon’s listings?

What medical products are hot on Amazon this season? As expected, as the pandemic continues, thermometers and masks are on buyers’ lists, but so are perennial products such as relaxation and fitness items. Many articles are digital health products, demonstrating the trend of deepening consumption. And you may even see some similarities to articles from our previous look at Amazon buying trends.

On December 21, the top 10 gift ideas in home medical supplies and equipment were:

  • Fitbit Inspire 2 Health & Fitness Tracker with 1-Year Free Fitbit Premium Trial, 24/7 Heart Rate, Black / Black, One Size (S and L Bands Included)
  • Fitbit Charge 5 Advanced Fitness & Health Tracker with Built-in GPS, Stress Management Tools, Sleep Tracker, 24 Hour Heart Rate & Up, Black / Graphite, One Size (S and L Bands Included)
  • AncestryDNA: genetic ethnicity test, ethnicity estimate, AncestryDNA test kit
  • 23andMe Ancestry + Traits Service: Personal genetic DNA testing with over 2000 geographic regions, family tree, relative DNA research, and trait reports
  • Fitbit Luxe Fitness and Wellness Tracker with Stress Management, 24/7 Sleep and Heart Rate Tracker, Black / Graphite, One Size (S and L Bands Included)
  • AncestryDNA + Traits: Genetic Ethnicity Test + Traits, AncestryDNA Test Kit with 35+ Traits, DNA Ancestry Test Kit, Genetic Test Kit
  • Black Disposable Masks 50PCS 3 Ply Breathable Filter Protection
  • KardiaMobile Single Lead Personal ECG Monitor | FDA Approved | Detects AFib
  • IHealth No-Touch forehead thermometer, digital infrared thermometer for adults and children, non-contact baby thermometer with 3 ultra-sensitive sensors, large LED display and soft vibration alert (PT3)
  • RENPHO Body Fat Scale Smart BMI Scale Wireless Digital Bathroom Weight Scale Body Composition Analyzer with Sync Smartphone App with Bluetooth 396 lbs – Black

Also on December 21, the top 10 most wanted home medical supplies and equipment were:

  • IHealth No-Touch forehead thermometer, digital infrared thermometer for adults and children, non-contact baby thermometer with 3 ultra-sensitive sensors, large LED display and soft vibration alert (PT3)
  • FYY Daily Pill Organizer, 7 Compartment Portable Travel Pill Organizer, [Folding Design] Pocket Purse Pill Box Holds Vitamins, Cod Liver Oil, Supplements & Medication – Blue
  • Elviros Memory Foam Neck Pillow, Contour Pillows for Neck and Shoulder Pain, Ergonomic Orthopedic Neck Support Pillow for Side, Back and Tummy Sleep (Blue-S)
  • Avana Kind Bed Orthopedic Support Wedge Pillow Comfort System, Blue / Gray
  • FridaBaby Fast Read Digital Rectal Thermometer
  • Neck and Shoulder Relaxer, Cervical Traction Device for TMJ Pain Relief and Cervical Spine Alignment, Chiropractic Neck Stretcher (Blue)
  • RENPHO Body Fat Scale Smart BMI Scale Wireless Digital Bathroom Weight Scale Body Composition Analyzer with Sync Smartphone App with Bluetooth 396 lbs – Black
  • Fitbit Inspire 2 Health & Fitness Tracker with 1-Year Free Fitbit Premium Trial, 24/7 Heart Rate, Black / Black, One Size (S and L Bands Included)
  • 23andMe Health + Ancestry Service: Personal genetic DNA testing, including health predispositions, carrier status, well-being, and trait reports (before purchasing, see important test information below below)
  • Non-contact forehead thermometer for adults and children, home digital infrared thermometer with fever indicator, instant accurate reading

And the top 10 sellers in home medical supplies and equipment on December 21 were:

  • Black Disposable Masks 50PCS 3 Ply Breathable Filter Protection
  • Zacurate Pro Series 500DL Fingertip Pulse Oximeter Blood Oxygen Saturation Monitor with Silicone Cover, Batteries and Lanyard (Royal Black)
  • Disposable face mask, black masks, 3-ply disposable face mask (200 pieces, black)
  • ApePal KN95 5-Layer Disposable Face Masks, Wide Elastic Earrings, Safety Face Mask, Black, 50 Pieces / Pack
  • Non-contact forehead thermometer for adults and children, home digital infrared thermometer with fever indicator, instant accurate reading
  • 100pcs Black Disposable Masks For Adults 3 Layer Non Woven Masks With Soft Elastic Earring
  • Wecolor 50 Disposable 3-Ply Earring Masks, Suitable for Home, School, Office and Outdoor (Black)
  • Black Face Mask 100pcs Disposable Masks Breathable 3-Layer Masks Mouth Cover for Adult Men and Women
  • 100pcs Black Disposable Face Mask 3 Ply Filter Protection Non-medical Face Masks Face Cover
  • Black disposable face masks, 3 ply face masks of 50 disposable masks

The listings above are only a snapshot taken on December 21, so be sure to click on the links for up-to-date rankings.

read more
Medical supplies

Fidelity Securities Limited donates medical supplies to Ghana Police Hospital

Fidelity Securities Limited, a subsidiary of Fidelity Bank Ghana Limited, donated medical supplies to the pediatric ward of the Ghana Police Hospital in Accra.

The supplies, including a CPAP machine, infuser, x-ray viewer, pulse oximeter, digital thermometer, pediatric ambubag, industrial nebulizer, oxygen concentrator (5L) and oxygen flow meter will help to provide health care to the children on the unit.

Presenting the articles at Ghana Police Hospital, Edward Opare-Donkor, Board Member of Fidelity Securities Limited, said: “Fidelity Securities Limited is more than grateful for being able to fulfill its civic duty in helping to save the lives of children across the country who visit the facility. Indeed, we are committed to supporting the government in providing the best health care to the people of Ghana.

Mr. Opare-Donkor noted that this was only the beginning of Fidelity Securities Limited’s relationship with the Ghana Police Hospital and he encouraged the Ghana Police Hospital to continue his selfless sacrifice to the nation.

Receiving the articles on behalf of Ghana Police Hospital, Dr Ebenezer Ewusi-Emmim, Medical Director of Ghana Police Hospital, said: “We appreciate Fidelity Securities Limited for supporting us with these valuable medical supplies at this very critical time. We will put these supplies to good use as we encourage them and other commercial institutions to continue to support us in delivering first class health services to the people of this country. “

FSL’s support to the Ghana Police Hospital is a demonstration of its commitment to the general well-being of Ghanaians through its social impact initiatives.

About Fidelity Securities Limited

Fidelity Securities Limited (FSL) is the asset management subsidiary of Fidelity Bank Ghana Limited. Licensed and regulated by the Securities and Exchange Commission of Ghana and the National Pensions Regulatory Authority, FSL is in good standing with regulators and other stakeholders.

The main goal of FSL is to give their clients financial freedom by undertaking well documented investments on their behalf. Having operated successfully for 15+ years, FSL fully understands the Ghanaian investment landscape and has a proven track record in creating sustainable investment portfolios, which create financial stability over time. FSL manages institutional funds (pensions, provident and endowment funds among others), collective investment schemes and individual asset portfolios.

At FSL, they are committed to demonstrating integrity, expertise and innovation to help their clients and communities grow to achieve their financial goals. This commitment is based on exceptional corporate governance standards, risk management practices, market knowledge, professionalism, proactivity and above all a customer-centric culture. Fidelity Securities was named Investment Fund Manager of the Year for the second consecutive time and Pension Fund Manager of the Year at the 2019 Ghana Accountancy and Finance Awards.

Website: www.fidelitysecuritieslimited.com.gh

Email: [email protected]

LinkedIn: https://www.linkedin.com/company/fidelity-securities-limited/

read more
Generic drugs

PODIUM | Bennet helps exempt generic drugs through BBB | Opinion






Maya wheeler


“About 18 million Americans, or 7% of American adults, say they recently couldn’t afford at least one prescription drug for their household, according to a new poll from Gallup and West Health.”

Democrats, Republicans and Independents grapple with even insured health care costs as prescription drug prices continue to rise. No one should be forced to choose between filling their prescriptions or their rent, gas, heat or food.

However, what is not clear is whether our elected officials choose between the people they represent and the Big Pharma lobbyists who write checks to their campaigns.

President Biden’s Build Back Better Act includes provisions that could go a long way toward implementing these long-promised drug reform policies. The new $ 35 cap on out-of-pocket expenses for insulin for patients on commercial or health insurance plans is a big step forward for vulnerable patients.

High drug prices disproportionately impact the sickest and poorest Americans. Nearly one in 10 Americans with three or more chronic conditions said they had to skip a drug purchase in the past three months, compared to about one in 25 people without any chronic illness, according to a Gallup poll. Skipping the purchase or rationing of drugs can be fatal. This was illustrated by NPR with the story of Nicole Smith-Holt, who lost her son three days before his next payday because he couldn’t afford to fill his insulin prescription. The price of insulin, which has no generic equivalent, has more than doubled since 2012. Those most in need of prescription drugs are also most likely to be negatively impacted by lack of access affordable drugs.

For minority communities, access to affordable insulin is an even bigger problem. Almost one in five black adults has diabetes, a rate more than double the white patient population. The high cost of care also contributes to a higher death rate. Black Americans die twice as fast as their counterparts from diabetes.

We have already seen the ugly health disparities in our system at the forefront of the COVID-19 pandemic, as patients of color have died at much higher rates than whites. Capping out-of-pocket spending will immediately benefit all patients, and especially those in the minority community who need help the most.

However, the Build Back Better Act is not perfect and some provisions could actually make drugs more expensive and less accessible. The inflation price rebate penalty looks good – drug makers should not be allowed to increase their prices more than the rate of inflation. But it really only works for brand name drugs, which have a government-protected monopoly. This allows companies making the most expensive drugs to set their prices as high as they want.

Generic drug makers, on the other hand, face much larger price fluctuations and a more competitive market, resulting in lower costs for consumers. And generic drug prices continue to decline on average year over year. The prices of brand-name drugs, meanwhile, continue to be “unsustainable, unjustifiable and unfair,” according to a recent report by Democrats in Congress. So it does not make sense to penalize a generic drug costing $ 1 for raising its price to $ 1.04, but to give a free pass to a large pharmaceutical company raising the price of its brand name drug by 10,000. $ to $ 10,299. As written, this is what the in-house version of the Build Back Better Act would do.

Fortunately, Senator Michael Bennet and his colleagues on the Senate Finance Committee took note and exempted generic drugs from the penalty. It is the right decision, politically and, more importantly, morally.

Generics and biosimilars account for 90% of prescriptions filled in the United States, but brand name drugs represent 80% of spending. For example, the osteoporosis drug Fosamax cost $ 2.60 per day or $ 80 per month. Now its generic version costs $ 0.28 per day, less than $ 9 per month.

These savings and the availability of cheaper drugs could be jeopardized by these new federal government policies if they are not changed. Low-income and working-class families, as well as seniors living on fixed incomes, would be at risk.

Senator Bennet has repeatedly shown his willingness to learn complex policies, understand its long-term impacts and make the necessary changes. The White House Biden should again heed his leadership and support the Senate version of the Build Back Better Act that makes the bill more patient-friendly.

Elected officials have been promising drug prices to drop for a long, long time. To come so close, and then fall victim to unintended political consequences thanks to the powerful lobbying of Big Pharma, would be a grave mistake.

Maya Wheeler is Executive Director of the African Chamber of Commerce, Colorado, and former Chair of the Colorado African American Democrats Initiative (AAICD) with the CO Democratic Party.

read more
Prescription drugs

Marijuana, Many Prescription Drugs Lead to Impaired Driving Chroniclers

December is National Impaired Driving Prevention Month. You’ve probably heard all about the dangers of drunk driving, but do you know the dangers of drunk driving? Driving under the influence of over-the-counter drugs, prescription drugs, marijuana, or any other mind-altering medication makes it dangerous to drive a vehicle.

Unfortunately, research indicates that the prevalence of the drug is on the rise among drivers. According to the trauma centers studied from October to December 2020, 56% of drivers involved in serious injuries or fatalities have tested positive for at least one drug.

How common is drug-impaired driving? After alcohol, marijuana is the most commonly used drug while driving. In 2020, 12.6 million people (aged 16 and over) are believed to have driven after using illicit drugs. Of that total, 11.7 million people were under the influence of marijuana. In another recent survey, 22% of teens admitted that driving with heavy marijuana use is common among their friends. 3.6 million young people between the ages of 16 and 25 admit to having driven under the influence of marijuana in the past year, according to the 2020 National Survey on Drug Use and Health. These statistics are of great concern, given that drugs such as marijuana affect the way people drive, endangering drivers, their passengers and others on the road. Drugs can affect a driver’s perception, attention, balance, coordination, reaction time, and other skills they need to stay alert and safe.

The National Highway Traffic Safety Administration’s Drug and Alcohol Crash Risk Study found that marijuana users are more likely to be involved in crashes. However, the increased risk may be due in part to the fact that marijuana users are more likely to be young men, who are generally at higher risk for accidents. Either way, research shows that marijuana slows reaction time, impairs driver focus and attention, and reduces hand-eye coordination. The THC in marijuana also interferes with a driver’s ability to multitask, an essential skill necessary for people behind the wheel.

Impaired driving can also occur after using prescription or over-the-counter medications such as cough suppressants, antihistamines, sleeping pills, and anti-anxiety medications. In some cases, even small amounts of these substances can impair driving skills by impairing perception, mental processes, attention, balance, coordination and other skills required for safe driving. For this reason, many prescription drugs have warning labels that advise against using machines and driving motor vehicles for a period of time after use.

Car crashes are the leading cause of death for people aged 16 to 19. PARENTS – warn your teenagers not to drive after using marijuana or other drugs, and not to get in a car with a driver who has used marijuana or other drugs! When teens’ driving inexperience is combined with the use of drugs that can affect cognitive and motor skills, the results can be tragic. Help protect your kids and your community this holiday season by helping to keep all impaired drivers off the roads.

Kelly Sickafoose is Secretary of the Northeast Regional Advisory Council of Community Anti-Drug Coalitions, Executive Director of Drug Free Adams County and Coordinator of Adams County Drug Court. She serves in an advisory capacity in LaGrange and Steuben counties. Contact her at [email protected]

read more
Medical supplies

Transportation congestion causing long delays for medical supplies

Hospitals and other providers are experiencing delays in delivering 8,000 to 12,000 containers of essential medical supplies and equipment, a setback that could negatively impact patient care and public health.

Healthcare resources are delayed on average for up to 37 days across the U.S. transportation system due to supply chain congestion, according to a study by the Health Industry Distributors Association.

Medical shipments are held in US ports for approximately 17 days. The ports of Long Beach and Los Angeles in California have the highest number of delayed medical containers on the West Coast. The port of Savannah, Georgia, is the most congested on the east coast, reports the association.

A shipping container contains approximately 190,000 medical gowns, 360,000 syringes and 3.5 million surgical gloves, according to HIDA estimates. These containers are delayed an average of 11 days per train and nine days per truck, according to the group of distributors.

The association currently represents 111 members, who manage logistics, provide customer service and deliver medical products and supplies, including 51 billion units of personal protective equipment last year.

Because unprecedented transportation disruptions have restricted the reliable and rapid movement of medical products, the Health Industry Distributors Association is working with several port associations and leaders to provide healthcare professionals and frontline workers with equipment faster and more. effectively, according to the group.

“HIDA recommends a rapid transit system to prioritize essential medical supplies via ports, rail and truck for expedited delivery to the front lines of healthcare,” said Matthew Rowan, President and CEO of HIDA, in a press release. “Rules and regulations that hamper the rapid and efficient movement of essential medical supplies must be relaxed during a public health emergency.”

read more
Medical supplies

Akande-Sadipe donates medical supplies and equipment to PHC

By Adedapo Adesanya

Nigerians have been urged to take collective responsibility as the country is currently experiencing a fourth wave of COVID-19.

This was revealed by the managing director of the Nigeria Center for Disease Control (NCDC), Dr Ifedayo Adetifa, in a statement.

“Nigeria has seen a 500% increase in the number of confirmed cases of COVID-19 in the past two weeks across the country, caused by the Delta and Omicron variants,” the statement said.

“As of December 19, 2021, a total of 223,887 cases and 2,985 deaths have been recorded in Nigeria in the 36 states and the Federal Capital Territory.

“The country is now in a fourth wave of COVID-19. The Federal Government of Nigeria, through the Presidential Steering Committee on COVID-19, the Federal Ministry of Health, as well as the NCDC and its partners, are therefore stepping up risk communication efforts to remind Nigerians of the risk. which we are faced with and must assume collective responsibility. to reduce the transmission of the virus, ”he added.

The NCDC said the response to the virus requires a collaborative approach.

“Therefore, individuals, families and institutions must also play their role to protect each other by ensuring compliance with public health and social measures related to COVID-19,” the statement said.

“Critically, Nigerians are urged to adhere to the measures recommended by the NCDC and other public health authorities as they celebrate Christmas and New Years.

“Please avoid all non-essential travel within and outside Nigeria to reduce the risk of transmission. The virus that causes COVID-19 is more likely to spread in mass gatherings, especially when kept indoors at full capacity and with poor ventilation.

“We strongly recommend outdoor events with physical distancing, the mandatory use of face masks, and the provision of hand washing facilities or hand sanitizers. Please take every opportunity available to you to get vaccinated against COVID-19. The government has made these vaccines available to all eligible citizens and booster doses available for those who have already been vaccinated, ”he added.

As part of its efforts against the virus, the NCDC said it was launching a Celebrate responsibly countryside.

“The Celebrate responsibly campaign which runs from Christmas holidays to the start of the new year, emphasizes the responsibility of all Nigerians, government, private sector, institutions, associations, communities, families and individuals in the fight against the COVID-19 pandemic, ”said the press release. .

“Religious leaders and heads of institutions, organizations and businesses are urged to enforce public respect for COVID-19 preventive measures in their jurisdiction. COVID-19 continues to threaten the lives and livelihoods of Nigerians, so we must not let our guard down this holiday season. We urge Nigerians to take all necessary precautions to ensure that we and our loved ones live to celebrate many other events and festivities.

“The campaign includes the production of key messages, audio and visual material for wide dissemination. The NCDC urges all individuals, traditional and religious leaders, business owners, media, transport workers and other institutions and sectors to join the campaign by adopting the key messages and sharing them within their networks.

“The Celebrate responsibly The campaign calls on all Nigerians to take all necessary precautions for a safe and healthy Christmas and New Year celebration, ”the agency added.

read more
Medical products

FTC to Survey Big Business Supply Chain Problems – Medical Products Supply Chain Weekly Review | Alston & Bird

Over the past two weeks, the Federal Trade Commission (FTC) has ordered major U.S. companies to provide information on problems and solutions in their supply chain. The FDA has issued an Emergency Use Clearance (EUA) for monoclonal therapy to include all children. An independent survey of pharmacies indicates that they still face supply chain issues. Please see details of these and other supply chain developments below:

  • On November 29, the FTC ordered nine major U.S. companies to provide the government with information about their supply chain operations. Specifically, the FTC is conducting an investigation to determine the reason for the delays. The FTC has asked companies to provide information on the main drivers of disruption in their supply chain and what they have done to address the issues. Companies have 45 days to respond.
  • On November 30, the FDA released a statement that discusses its omicron variant surveillance plan. The plan includes ongoing reporting by stakeholders of the impact of the variant on testing, vaccines and treatments. Currently, the FDA expects the variant to have a low impact on testing capabilities and infrastructure. The information will be released to the public as soon as it becomes available.
  • On December 3, the FDA expanded the EUA for two monoclonal antibodies – bamlanivimab and etesevimab (used in combination) – to include treatment of all pediatric patients, including newborns, who test positive for the COVID test -19 and are at high risk of progression to severe COVID-19. The combination drug is now also authorized for post-exposure prophylaxis for the prevention of COVID-19 in all pediatric patients, including newborns, at high risk of progression to severe COVID-19. The move comes after the FDA evaluated the results of clinical trials that showed the therapy to be safe and effective.
  • On December 3, the Federal Reserve released a note based on a textual analysis of earnings calls to account for the effects of the supply chain bottleneck on prices. Call SMS messages won from the S&P Global Market Intelligence database were searched for certain terms and were classified as positive impact or negative impact. Additionally, the authors used a regression model to analyze the impact of supply bottlenecks on concerns. The authors’ findings suggest that the global container shortage is the primary concern of most industries, and that the automotive sector suffers the most negative impacts. In an analysis of companies facing large supply chain disruptions versus low disruptions, those that experienced large disruption experienced statistically significant price increases. Overall, stronger global demand, supply bottlenecks and chip shortages had the biggest effect on prices. It is important to note that capacity issues and shipping bottlenecks have not resulted in price increases due to the increase in mentions in calls.
  • On December 8, the FDA issued an EUA for AstraZeneca’s Evusheld, an injectable drug combined with monoclonal antibodies. The authorization is for use in adults and adolescents 12 years of age and older who also have moderately to severely compromised immune systems or whose vaccination is not recommended due to serious side effects. Data from a clinical trial have shown a 77% reduction in the risk of contracting COVID-19 after treatment, with efficacy lasting up to six months.
  • On December 8, the FDA released a draft guideline titled “Considerations for Using Real Data and Evidence to Support Regulatory Decision Making for Drugs and Biologics”. The goal of the guidance, which would meet a mandate under the 21st Century Cures Act of 2016, is to facilitate increased efficiency in the approval of new indications for legally marketed drugs. Sponsors are encouraged to contact the FDA to discuss their draft study protocol and statistical analysis plan for review and comment before finalizing the documents. Additionally, sponsors need to consider and address data privacy concerns using real world data.
  • On December 9, the Treasury Department’s Office of Foreign Assets Control (OFAC) imposed sanctions on foreign government officials and entities on the International Anti-Corruption Day. The initiative targets, among others, heads of state and entities that have participated in acts of corruption in the context of “COVID-19 purchases”. Specifically, officials who have engaged in bribery programs, inflation in the prices of medical devices and PPE, and improper awarding of contracts are subject to sanctions. Government officials and their families have also faced sanctions for US visas.
  • On December 9, at the Food and Drug Law Institute’s Enforcement, Litigation and Compliance conference, Elizabeth Miller of the FDA, deputy commissioner for medical products and tobacco operations in the Office of Regulatory Affairs, spoke revealed that the agency is planning a pilot program to conduct unannounced inspections in India and expand the program to China.
  • On December 10, the Department of Transportation announced that the agency had awarded $ 12.6 million in America’s Marine Highway (AMHP) grants to nine maritime highways to help deal with disruption in the water supply chain. supply and movement of goods. AMHP, which operates as a public-private partnership, seeks to reduce land congestion, support transport options and improve the performance of the transport system. Some specific projects mentioned include funding for a New York / New Jersey barge project to increase trailer transportation, increasing the operational capacity of the Richmond, Virginia marine terminal, and upgrading ship equipment. a marine terminal in North Carolina.
  • On December 10, the Center for Devices and Radiological Health released a discussion paper titled “Point-of-Care 3D Printing of Medical Devices.” The paper provides background, an overview of how these devices might be approved for point-of-care use, and the challenges of this approach. The authors also ask 16 questions on which they would like to receive comments. Public comments are expected on February 8, 2022.
  • On December 16, the FDA released a draft guideline, “Inspection of Injectables for Visible Particles: Draft Guidance for Industry.” The guidelines aim to provide industry with risk-based procedures to “assess, correct and prevent the risk of visible particulate contamination”. Serious adverse events have been observed following injectables contaminated with visible particles. Manufacturers performing risk assessments and implementing mitigation strategies for injectables containing visible particles should consider the type of particles, container components and closure systems, and quality assurance procedures, among other factors. Comments are due by February 14, 2022.
  • The International Coalition of Drug Regulators has published an article from its COVID-19 Working Group, “Remote PCB and GMP Regulatory Oversight Inspections”. The document provides an assessment of how regulators provided remote monitoring during the pandemic, the challenges of implementation, and the success of the programs. The Working Group noted that while the possibilities offered by remote monitoring facilitate new monitoring methods, they should not replace traditional inspections. However, there is room for supplementation with these new tools.
  • The National Community Pharmacists Association has released the results of a survey showing that supply chain issues continue to plague 60% of independent pharmacies. In addition to these disruptions, independent pharmacies continue to flag staff, low reimbursement rates and market forces as reasons for their concern. Supply chain disruptions have increased consumer wait times for prescriptions. Overall, 41% of respondents felt that the state of the industry can be classified from bad to very bad.
  • Amazon has invested in a private supply chain network that has helped the company bypass supply chain issues. The company uses charter freighters, its own shipping containers, ships that bypass the busiest ports of Los Angeles and Long Beach, and planes that bypass ports completely. By serving as its own shipping provider, Amazon can use less busy ports for deliveries and is not dependent on container availability and access by third-party shipping companies. Amazon is now estimated to ship 72% of its merchandise. In addition, Amazon has increased the number of vacation rentals by 50% and increased the number of new installations.

[View source.]

read more
Prescription drugs

Marijuana use could make prescription drugs ineffective

Using marijuana may reduce the effectiveness of some common medications, including popular over-the-counter drugs and others used to treat breast cancer, according to an expert.

Dr Philip Lazarus, a pharmaceutical scientist at Washington State University, told UPI his team found in laboratory research that the use of marijuana can either overburden or even reduce , the effectiveness of drugs in a human system.

Common medications like Tylenol, Motrin – or other ibuprofens – or blood thinners could be too effective when interacting with marijuana and potentially harm the user.

On the other hand, an often used breast cancer drug can be rendered ineffective when it interacts with cannabis.

The results are worrisome, as many people use marijuana to relax and even manage pain. The use of the drug has become common in recent years, and research shows that it could cause harm to some people who need these drugs on a daily basis.

Marijuana could interact with certain pain relievers or drugs for the treatment of breast cancer in ways that could be dangerous. The drug interacts with Tylenol and Ibuprofen in a way that could damage the liver. For people who use the breast cancer drug tamoxifen, marijuana may reduce the drug’s effectiveness (file photo)

“We have seen significant inhibitions,” Lazarus told UPI.

“The concentrations that we see in the lab are probably an indicator that there is at least some inhibition of these enzymes in real time.”

They looked at how two chemicals found in marijuana, CBD and THC, interact with enzymes and other bodily functions that allow a person’s body to break down these chemicals.

Warfarin, for example, is a blood thinner often used by people with blood clots.

If the drug interacts with CBD, it becomes so effective that it can become dangerous.

– That one, you’re not joking with. Effects of too high a level, even transiently, for a few days can be fatal, ”University of Buffalo professor Ed Bednarczyk told UPI.

“It’s king of the hill for risk, because it’s everywhere in terms of patient-to-patient variability.”

Marijuana can also enhance the effects of ibuprofen. Although over-the-counter medications are generally safe in normal doses, they can become problematic for a person’s kidneys if overused.

When interacting with cannabis, ibuprofen or other pain relievers like Tylenol become extremely effective – almost too effective – and can damage the liver.

‘[Ibuprofen] is toxic to your liver and kidneys anyway, but you start taking marijuana on top of that, then you will see significant effects, ”Lazarus said.

“It would probably cause toxicity because you slow down its metabolism, which means you don’t excrete the substance and you have more of it in your body.”

Tamoxifen, a drug used to treat breast cancer, has the opposite interaction with marijuana.

Tylenol and other pain relievers could be commonly used, making marijuana use a potential danger for some (file photo)

Tylenol and other pain relievers could be commonly used, making marijuana use a potential danger for some (file photo)

Researchers have found that marijuana can negatively impact the enzymes a person’s body uses to break down drugs.

If the drug is not broken down enough in a person’s body, it will not get the full benefit of it, which will prevent the person from receiving the full amount of treatment they expect.

This can be all the more worrying given that many breast cancer patients using marijuana for pain management, and to relieve stress, while receiving treatment for their illness.

These findings are of concern to people who regularly use these drugs and consume marijuana, and Lazarus wants to further study these interactions between marijuana and prescription and over-the-counter drugs.

“We need to do clinical studies to show people that if you take a specific drug and also smoke a marijuana cigarette that morning, you see higher or lower levels of that drug in your body,” a- he declared.

The use of marijuana in the United States has increased dramatically in recent years as it slowly gains legalization and decriminalization across the country.

A study published earlier this year, which gathered data from 2017, found that more than 15% of Americans had used marijuana in the past year and that the number of people who used it daily had doubled between 2006 and 2016.

read more
Prescription drugs

DEA chief warns of fake prescription drugs containing fentanyl

WASHINGTON – Mexican drug cartels are flooding the U.S. market with fake prescription pills containing fentanyl, resulting in thousands of overdoses and deaths, according to the Drug Enforcement Administration (DEA).

During a press conference Thursday afternoon, DEA administrator Anne Milgram, JD, said that one morning in May this year, the parents of a 15-year-old freshman in high school in the ‘Idaho “found their son in his bedroom. He was not breathing. Although he started CPR right away and immediately called for help, their son died of a fentanyl overdose. “

The boy’s death was caused by a pill he bought on Snapchat – “a pill he thought was prescription oxycodone,” she continued. “It looked like a prescription oxycodone pill, but it wasn’t. It was actually a fake pill with a lethal dose of fentanyl in it.”

Deaths like this happen every day in the United States, Milgram said. “We know that these overdose deaths are directly caused by the Mexican drug cartels flooding the United States with millions of fake pills” containing large amounts of fentanyl powder. “Mexican drug networks get a lot of chemicals from China, then they mass produce – often in industrial labs – these lethal substances in Mexico, then pump that poison into the United States. And they are killing tens of thousands of Americans. “

“Equally disturbing is that the cartels have exploited the perfect drug delivery tool – social media apps that are available on every smartphone in the United States,” she said, adding that “85% of all Americans have smartphones … When you open Snapchat, when you open Facebook, when you open Instagram, when you open TikTok, when you open YouTube, drug dealers and criminal networks are waiting for you. “

The cartels “target people of all ages: a curious teenager ordering a pill online, a college student trying a friend’s pill, an elderly neighbor looking online for a pain reliever,” Milgram said. They use social media because “it’s widely available, it’s easy to use, and drug dealers can hide their identities … And most importantly, the sites allow the sale of these fake counterfeit pills every day without control”.

“These criminal drug networks distort what they sell,” she added. “People think they are buying real Xanax pills, real Adderall pills, real oxycodone using online platforms they trust, when in reality they are getting lethal fentanyl in pills that look like to the real thing. “

To tackle the problem, “Last Tuesday, just 2 days ago, the DEA completed a wave of public safety – our second since August – to target the most dangerous drug traffickers and drug networks. pushing deadly drugs in our country, “says Milgram.” Our investigations revealed that these networks were directly linked to 39 overdose deaths, and 76 of our investigations involved drug-related criminal activity on Facebook and Facebook Messenger, on Snapchat, Instagram, TikTok, YouTube and other social media platforms. “

In total, from September 29 to December 14, the agency seized more than 8.4 million fake pills, more than 5,400 pounds of methamphetamine and hundreds of pounds each of cocaine, heroin and marijuana, “often at the same places we grabbed the fentanyl, “she said. And 2 days before the press conference,” DEA agents in Arizona seized about 1.7 million pills and 13 pounds of fentanyl in one go . I have no doubts that DEA officers and Task Force officers have avoided a significant number of overdoses and overdoses. death with just this seizure. “

On September 27, the agency issued its first public safety alert in 6 years to warn people of fake pills. So far in 2021, the DEA had seized 9.5 million fake pills, more than in the previous 2 years combined.

Milgram urged the public to be part of the solution. “Know the dangers – and the accessibility – of deadly drugs online,” she said. “Never take drugs that have not been prescribed for you personally and filled by a licensed pharmacist. Spread the word that a pill can kill.”

  • Joyce Frieden oversees the coverage of MedPage Today in Washington, including articles about Congress, the White House, the Supreme Court, health professional associations and federal agencies. She has 35 years of experience in health policy. To follow

read more
Medical supplies

HIDA: Millions of essential medical supplies delayed at congested ports

Congestion at ports is creating a crisis for the country’s medical providers. The Health Industry Distributors Association (HIDA) told American Shipper that between 8,000 and 12,000 containers filled with millions of essential medical supplies are being delayed.

According to HIDA, these containers are on average 37 days late.

“COVID is always with us and it is difficult to predict the evolution of particular variants and their impact on supplies,” said HIDA President and CEO Matthew J. Rowan. “So the best strategy is for the supply chain to maintain readiness and for distributors and manufacturers to continue to get medical supplies to suppliers. “

Federal Maritime Commissioner Carl Bentzel told American Shipper he had received letters and held follow-up meetings with representatives from HIDA, the Advanced Medical Technology Association (AdvaMed) and the International Safety Equipment Association (ISEA), all highlighting the need shipping abroad and begging for help. for port managers to identify and prioritize medical supply containers for quick pickup.

“Although the CMF does not have the legal authority to prioritize freight, these containers contain essential products for the health, safety and well-being of our country’s frontline medical workers, as well as patients.” , said Bentzel. “President [Daniel] Maffei realizes this and we at the CMF have had several meetings on the issue and are committed to doing what we can to help healthcare providers receive these vital products.

“The Biden administration has also helped, and we are in contact with John Porcari [port envoy to the White House Supply Chain Disruptions Task Force] on the project to ensure the delivery of essential health products to American hospitals ”

Bentzel said he contacted Port of Los Angeles Executive Director Gene Seroka and Port of Long Beach Executive Director Mario Cordero, as well as SSA Marine, the second largest container terminal operator in the Americas, to find means of prioritizing the cargo and accelerating its movement inland.

In March 2020, Seroka was chosen by Los Angeles Mayor Eric Garcetti to be responsible for City of Los Angeles logistics and he oversaw the Logistics Victory Los Angeles (LoVLA) response effort which assisted obtain essential personal protective equipment (PPE) and emergency services. supplies to healthcare and supply chain workers.

“These port managers were the first to identify and move containers full of PPE and other health care and disinfection supplies at the onset of the pandemic,” Bentzel said. “Gene and Mario immediately agreed to help and set up teams at the port to move the product. They are in the process of identifying the containers. SSA is in the process of labeling the containers and using peel piles for expedited pickup.

Seroka told American Shipper, “These supplies are more vital than ever as the omicron variant spreads across the country. HIDA has contacted us to identify the containers to be shipped. We use our digital system to identify these containers so that we can move them as quickly as possible.

“Unfortunately, these boxes are mixed with the thousands of import containers arriving at the port. The sooner we know when these containers are arriving, the more effective we can be in fending off these valuable imports. “

Cordero said: “Since the start of the pandemic, the Port of Long Beach, in partnership with the marine terminal operators and the stevedoring workforce, has been able to expedite shipments of PPE, supplies medical and medical equipment. Everyone has worked together to help these life-saving shipments get to hospitals and healthcare professionals as quickly as possible. This remains a priority for the entire port community.

One of the terminals playing a key role in this supply chain mission, according to Bentzel, is SSA Marine Terminals.

Sal Ferrigno, vice president of SSA Marine Terminals, explained that the terminals electronic platform is used to identify containers.

“In an effort to ensure the availability of essential supplies for our country, we have prioritized medical supplies at our terminals,” Ferrigno said. “The solution is simple with the help of eModal. We are able to identify containers with medical equipment before they arrive.

“Once unloaded from a ship, the containers are given a priority appointment where, once they leave the gate, they will be taken to their destination. The process is safe, efficient, and fast, especially when you consider the omicron virus outbreak and the need for medical supplies. “

According to the HIDA transit analysis, congestion along the east coast is also hampering the logistical efforts of medical providers. HIDA told American Shipper that Savannah, Georgia had the most delays, followed by New York and New Jersey.

“We spoke with Sam Ruda from the Port of New York / New Jersey and Griff Lynch from the Port of Savannah and warned them something like this was going to happen to them,” said Bentzel. “We are in the early stages of these ports. “

Bentzel also communicated with the World Shipping Council on this logistics mission.

“I plan to do a presentation to their members on our need for their assistance in the accelerated movement of this essential cargo,” said Bentzel. “In this insistence, we do not have adequate levels of US flag vessels under ultimate government control to assist, but I am asking for support for the delivery of this cargo.

“The success of this initiative must involve the World Shipping Council and potentially other US coastal ports such as Savannah and New York / New Jersey. At first, they were responsive, and hopefully progress on the West Coast can lead to a heightened national effort. HIDA says hospitals urgently need these products. All facets of the maritime community should work together on this medical logistics mission. “

read more
Medical supplies

HIDA: Millions of critical medical supplies delayed in congested ports

Congestion at ports is creating a crisis for the country’s medical providers. The Health Industry Distributors Association (HIDA) told American Shipper that between 8,000 and 12,000 containers filled with millions of essential medical supplies are being delayed.

According to HIDA, these containers are on average 37 days late.

“COVID is always with us and it is difficult to predict the evolution of particular variants and their impact on supplies,” said HIDA President and CEO Matthew J. Rowan. “So the best strategy is for the supply chain to keep readiness and for distributors and manufacturers to keep medical supplies moving to suppliers.”

Special FREE Masterclass! How to get started in trading in 2022 with Matt Maley! Register now!

Federal Maritime Commissioner Carl Bentzel told American Shipper he had received letters and held follow-up meetings with representatives from HIDA, the Advanced Medical Technology Association (AdvaMed) and the International Safety Equipment Association (ISEA), all highlighting the need shipping abroad and begging for help. for port managers to identify and prioritize medical supply containers for quick pickup.

“Although the CMF does not have the legal authority to prioritize freight, these containers contain essential products for the health, safety and well-being of our country’s frontline medical workers, as well as patients.” , said Bentzel. “President [Daniel] Maffei realizes this and we at the CMF have had several meetings on the issue and are committed to doing what we can to help healthcare providers receive these vital products.

“The Biden administration has also helped, and we are in contact with John Porcari [port envoy to the White House Supply Chain Disruptions Task Force] on the project to ensure the delivery of essential health products to American hospitals “

Bentzel said he contacted Port of Los Angeles Executive Director Gene Seroka and Port of Long Beach Executive Director Mario Cordero, as well as SSA Marine, the second largest container terminal operator in the Americas, to find means of prioritizing the cargo and accelerating its movement inland.

In March 2020, Seroka was chosen by Los Angeles Mayor Eric Garcetti to be responsible for City of Los Angeles logistics and he oversaw the Logistics Victory Los Angeles (LoVLA) response effort which assisted obtain essential personal protective equipment (PPE) and emergency services. supplies to healthcare and supply chain workers.

“These port managers were the first to identify and move containers full of PPE and other health care and disinfection supplies at the onset of the pandemic,” Bentzel said. “Gene and Mario immediately agreed to help and set up teams at the port to move the product. They are in the process of identifying the containers. SSA is in the process of labeling the containers and using peel piles for expedited pickup. “

Seroka told American Shipper, “These supplies are more vital than ever as the omicron variant spreads across the country. HIDA has contacted us to identify the containers that need to be shipped. We use our digital system to identify these containers so that we can move them. get out as quickly as possible.

“Unfortunately, these boxes are mixed in with the thousands of import containers arriving at the port. The sooner we know when these containers are arriving, the more effective we can be in fending off these valuable imports.”

Cordero said: “Since the start of the pandemic, the Port of Long Beach, in partnership with the marine terminal operators and the stevedoring workforce, has been able to expedite shipments of PPE, supplies medical and medical equipment. Everyone has worked together to help these vital shipments reach the hands of hospitals and healthcare professionals as quickly as possible. This remains a priority for the entire port community.

One of the terminals playing a key role in this supply chain mission, according to Bentzel, is SSA Marine Terminals.

Sal Ferrigno, vice president of SSA Marine Terminals, explained that the terminals electronic platform is used to identify containers.

“In order to ensure the availability of essential supplies for our country, we have prioritized medical supplies at our terminals,” Ferrigno said. “The solution is simple with the help of eModal. We are able to identify containers with medical equipment before they arrive.

“Once unloaded from a ship, containers are given a priority appointment where once out of the gate they will be taken to their destination. The process is safe, efficient and fast, especially considering the omicron virus outbreak and the need for medical equipment. “

According to the HIDA transit analysis, congestion along the east coast is also hampering the logistical efforts of medical providers. HIDA told American Shipper that Savannah, Georgia had the most delays, followed by New York and New Jersey.

“We spoke with Sam Ruda from the Port of New York / New Jersey and Griff Lynch from the Port of Savannah and warned them something like this was going to happen to them,” Rowan said. “We are in the early stages of these ports.”

Bentzel also communicated with the World Shipping Council on this logistics mission.

“I plan to do a presentation to their members on our need for their assistance in the accelerated movement of this essential cargo,” said Bentzel. “In this insistence, we do not have adequate levels of US flagged ships under ultimate government control to help, but I am asking for support for the delivery of this cargo.

“The success of this initiative must involve the World Shipping Council and potentially other US coastal ports such as Savannah and New York / New Jersey. Beforehand, they have been responsive and hopefully progress on the West Coast can lead to increased national effort HIDA says hospitals urgently need these products All facets of the maritime community should work together on this medical logistics mission.

Image from Pixabay

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

read more
Generic drugs

Studies Proving Generic Drugs Can Fight COVID Dropped

The emergence of Omicron in the United States and the announcement of the first reported death in the United Kingdom reminds us of how little we understand about the new coronavirus, and with less effective vaccines against the new variant, how much we have need additional resources to combat it. To expand our knowledge about COVID-19 and identify the best ways to treat and prevent it, physicians should be able to use all the safe means available to them to help patients. Unfortunately, this is not possible in our current political climate.

Since the summer of 2020, US public health agencies have continuously shut down the use or even discussion of unprofitable generic treatments. The National Institutes of Health (NIH) funded 20 large pharmaceutical industry patented drug research studies before only recently (and slowly) agreed to study reused generic drugs.

The Food and Drug Administration and the Centers for Disease Control have not recommended any recommendations. Instead, the Biden administration threw its political clout almost solely behind mass vaccinations, and hospitals and pharmacies dogmatically followed suit. But this approach is not enough to stop COVID-19.

Reused Generic Drugs That Help Fight COVID

Just look at the evidence on fluvoxamine, a widely used generic antidepressant. A randomized controlled trial (RCT) published in November 2020 showed that the drug caused much less clinical deterioration in treated patients. Another larger, double-blind RCT, published in The Lancet in October this year, found that fluvoxamine reduced COVID-19-related death rates by up to 91% and hospitalizations by two-thirds. This is an FDA approved drug. Dosed correctly and for such short periods of time, it is safe. And it costs about a dollar a pill.

These findings have since been further reinforced by another study published by the Journal of the American Medical Association in November, which showed a strong “class effect” of the benefits of antidepressants very similar to fluvoxamine against COVID-19. Yet despite the large, double-blind, placebo-controlled trial, neither the NIH nor the Infectious Diseases Society of America (IDSA) have come up with a recommendation for the routine use of these drugs to treat COVID-19.

The NIH to date has ignored the study. His last update on fluvoxamine was in April, over seven months ago. More troubling is the fact that the IDSA recently reviewed this high-quality trial, while staying true to its recommendation “not to use outside of a clinical trial”. Why do reused drugs require multiple trials before an agency’s recommendation, while new, high-profit, patented drugs are routinely approved after just one trial?

A recent and more cheeky example is Merck’s expensive new COVID-19 antiviral drug, molnupiravir. The FDA quickly approved it based on a single study of modest benefit in mildly ill outpatients, and the Biden administration quickly agreed to pay $ 700 per treatment. This was all despite the fact that the drug costs around $ 20 per course to manufacture, according to a consultant to the World Health Organization, and may prove to be less effective or even harmful in practice.

With our national debt standing at $ 2.77 trillion and skyrocketing inflation, strengthening our federal government’s capacity to study inexpensive generic drugs would be a smart economic move. But it seems there is no appetite for fiscal prudence or scientific research beyond the expensive and newly created solutions by our country’s pharmaceutical industry.

Hospital bans proven treatment

Doctors who don’t respect the line are subject to censorship and threatened with losing their livelihood, regardless of their clinical experience. My colleague Dr Paul Marik, a medical scientist practicing in Norfolk, Virginia, is one of them. He has treated patients throughout the COVID epidemic and was one of the early advocates of the use of steroids to treat COVID patients – a practice initially discouraged by federal health officials who turned since proven effective.

When evidence first emerged about fluvoxamine, we began to study the drug and share clinical data with doctors from the Frontline COVID-19 Critical Care Alliance (FLCCC), a group of doctors for the purpose non-profit that we run together. We added it to our FLCCC protocol seven months ago. Marik began treating his patients with the drug in addition to steroids and a number of reused generic drugs, which helped halve the number of deaths in his hospital.

This progress is now at risk: Marik’s employer Sentara Norfolk General Hospital has banned the use of fluvoxamine along with several other generic drugs approved by the FDA to treat COVID-19 – and death rates are already increasing.

What is the hospital’s rationale for denying patients treatment that has proven to be effective in clinical trials? It sounds a lot like the NIH website and sounds just as hollow: “A lot [of these medicines] have not published peer reviewed, RCT [randomized controlled trial] available to assess both the efficacy and safety of COVID-19. “

Over the past two years, our political and public health authorities have spoken often of trusting science to guide an effective response to this terrible virus, but their actions have more often been dictated by tribalism and greed.

We will surely face new variants of COVID-19 after Omicron and other infectious disease outbreaks in the future. We can prepare by strengthening our government’s ability to study cost-effective treatments quickly and efficiently, and by empowering physicians to pursue all possible treatments that can help patients.

Pierre Kory, MD, is President and Chief Medical Officer of the Front-Line COVID-19 Critical Care Alliance.

read more
Generic drugs

Global Generic Inhalation and Nasal Spray Market Expected to Reach Over $ 10 Billion by 2026 – ResearchAndMarkets.com

DUBLIN – (COMMERCIAL THREAD) – The report “Generic Inhalation Drugs and Nasal Sprays Market Research Report by Indication, Age Group, Class, Route, Distribution Channel and Region – Global Forecast to 2026 – Cumulative Impact of COVID -19 “has been added to ResearchAndMarkets.com offer.

The global generic inhalation and nasal spray market size was estimated to be USD 6,392.52 million in 2020, is expected to reach USD 6,879.55 million in 2021, and is expected to grow at a CAGR of 7.95% to reach 10,119 , 95 million USD by 2026.

Market statistics

The report provides market size and forecast in five major currencies: USD, EUR GBP, JPY, and AUD. It helps organizational leaders make better decisions when currency data is readily available. In this report, the years 2018 and 2019 are considered as historical years, 2020 as the base year, 2021 as the estimated year and the years 2022 to 2026 are considered as the forecast period.

Market segmentation and coverage

This research report categorizes Generic Inhalation Drugs and Nasal Sprays to forecast revenue and analyze trends in each of the following submarkets:

  • Based on the indication, the market has been investigated for allergic rhinitis, asthma and COPD.

  • Based on age group, the market has been researched among adults, children 2-5 years old, and children 6-12 years old.

  • Based on the class, the market has been studied for allergy blockers, anticholinergics, antihistamines, decongestants, mast cell inhibitors, and nasal steroids.

  • Based on Route, the market has been investigated for inhalation, nasal spray, and tropical lotion.

  • Based on the distribution channel, the market has been studied in hospital medical stores, online pharmacies and retail pharmacies.

  • Based on the region, the market has been studied in the Americas, Asia-Pacific and Europe, Middle East and Africa. The Americas are studied in more detail in Argentina, Brazil, Canada, Mexico and the United States. The United States is studied in more detail in California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. Asia-Pacific is further explored in Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, the Middle East and Africa are studied in more detail in France, Germany, Italy, the Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates and United Kingdom.

Companies mentioned

  • Allergan plc

  • Altaire Pharmaceuticals inc.

  • Beximco Pharmaceuticals Ltd.

  • Catalent Pharma Solutions

  • Cipla Limited

  • Hikma Pharmaceuticals PLC

  • Mylan NV

  • Navajo Manufacturing Company Inc.

  • Pharmaceutical company Nephron

  • Perrigo Company plc

  • Preferred Pharmaceuticals Inc.

  • Sandoz International GmbH

  • Sheffield Pharmaceuticals LLC

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

Cumulative impact of COVID-19

COVID-19 is an incomparable global public health emergency that has affected nearly all industries, and the long-term effects are expected to impact the growth of the industry during the forecast period. The analyst’s ongoing research is amplifying their research framework to ensure the inclusion of the underlying issues of COVID-19 and potential avenues to follow. The report provides insight on COVID-19 given changes in consumer behavior and demand, purchasing patterns, supply chain diversion, dynamics of current market forces, and significant government interventions. . The updated study provides information, analysis, estimates and forecasts, considering the impact of COVID-19 on the market.

Competitive strategic window

The Competitive Strategy Window analyzes the competitive landscape in terms of markets, applications and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for suppliers to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to continue the expansion and growth of the business during a forecast period.

FPNV positioning matrix

The FPNV Positioning Matrix assesses and ranks vendors in the Generic Inhalation and Nasal Spray market based on business strategy (company growth, industry coverage, financial viability, and channel support) and product satisfaction (value for money, ease of use, product features) and customer support) which helps businesses make better decisions and better understand the competitive landscape.

Market share analysis

The market share analysis offers the analysis of the suppliers considering their contribution to the overall market. It provides the idea of ​​its revenue generation in the overall market compared to other space providers. It provides insight into the performance of vendors in terms of revenue generation and customer base compared to others. Knowing the market share gives an idea of ​​the size and competitiveness of the suppliers for the base year. It reveals the characteristics of the market in terms of traits of accumulation, fragmentation, dominance and fusion.

Competitive scenario

The competitive scenario provides a outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section delivers valuable insights at different stages while staying up to date with the business and engaging stakeholders in the economic debate. The competitive scenario represents press releases or news from companies categorized as M&A, Agreement, Collaboration and Partnership, New Product Launch and Improvement, Investment and Funding, and Reward, Recognition and Expansion. All the news gathered helps the supplier understand the market gaps and the strengths and weaknesses of the competitors, thus providing information to improve products and services.

Main topics covered:

1. Preface

1.1. Objectives of the study

1.2. Market segmentation and coverage

1.3. Years taken into account for the study

1.4. Currency and price

1.5. Language

1.6. Limits

1.7. Hypotheses

1.8. Stakeholders

2. Research methodology

3. Executive summary

4. Market overview

4.1. introduction

4.2. Cumulative impact of COVID-19

5. Market dynamics

5.1. introduction

5.2. Conductors

5.2.1. Low cost associated with generic prescription drugs

5.2.2. Increased prevalence of asthma and COPD disorders

5.2.3. High cost of health care in developed regions

5.3. Constraints

5.3.1. Strict regulations for generic drugs

5.4. Opportunities

5.4.1. Successful drug patents expire and FDA approvals increased

5.4.2. Trend towards generic drugs in developed countries due to rising cost of health care

5.5. Challenges

5.5.1. Pressure on prices due to the presence of several players in the segment

6. Generic Inhalation and Nasal Sprays Market, by Indication

6.1. introduction

6.2. Allergic rhinitis

6.3. Asthma

6.4. COPD

7. Generic Inhalation Nasal Spray Drugs Market, By Age Group

7.1. introduction

7.2. Adults

7.3. Children 2 to 5

7.4. Children 6 to 12

8. Generic Inhalation and Nasal Spray Drugs Market, By Class

8.1. introduction

8.2. Allergy blocker

8.3. Anticholinergic

8.4. Antihistamine

8.5. decongestant

8.6. Mast cell inhibitor

8.7. Nasal steroid

9. Generic inhalation and nasal sprays market, by road

9.1. introduction

9.2. Inhalation

9.3. Nasal spray

9.4. Tropical Lotion

10. Generic inhalation and nasal sprays market, by distribution channel

10.1. introduction

10.2. Hospital medical store

10.3. Online pharmacy

10.4. Retail pharmacy

11. America Generic Inhalation and Nasal Spray Market

12. Asia-Pacific Generic Inhalation and Nasal Spray Market

13. Europe, Middle East & Africa Generic Inhalation Drugs and Nasal Sprays Market

14. Competitive landscape

14.1. FPNV positioning matrix

14.1.1. Quadrants

14.1.2. Business strategy

14.1.3. Product satisfaction

14.2. Market ranking analysis

14.3. Market share analysis, by key player

14.4. Competitive scenario

14.4.1. Merger & Acquisition

14.4.2. Agreement, collaboration and partnership

14.4.3. New product launch and improvement

14.4.4. Investment and financing

14.4.5. Awards, recognition and expansion

15. Company usability profiles

For more information on this report, visit https://www.researchandmarkets.com/r/1lry5e

read more
Medical supplies

India in contact with Pakistan to send wheat, medical supplies to Afghanistan, MEA says

Packages containing medical supplies to be sent to Afghanistan on December 11, 2021 | Photo PTI

Text size:

New Delhi: India is in contact with Pakistani authorities to send more humanitarian aid, including wheat and life-saving medicines to Afghanistan, the Foreign Ministry said Thursday.

“We will continue to provide humanitarian aid to Afghanistan. We have pledged to send 50,000 metric tonnes of wheat to Afghanistan, ”MEA spokesman Arindam Bagchi said during his weekly press briefing here. “India is in contact with Pakistani authorities on the terms of shipping 50,000 tonnes of wheat and other medical supplies to Afghanistan by land,” Bagchi said.

The spokesperson, however, did not explain why India had not used the Iranian port of Chabahar to ship wheat through Iran.

Bagchi reiterated that India has a special relationship with the Afghan people and that UN Security Council Resolution 2593 will continue to guide India’s approach to Afghanistan.

Bagchi also noted that India shipped around 1.6 tons of medical supplies as humanitarian aid to Afghanistan on December 11 and that they were handed over to World Health Organization officials in Kabul. .

Pakistan decided in November this year to allow India to transport 50,000 metric tonnes of wheat and other humanitarian goods to Afghanistan via the Wagah border, which Islamabad claims was done as a “exceptional”, given the humanitarian crises in Afghanistan.

The Taliban took control of Kabul on August 15 and as a result the country was hit by a worsening economic, humanitarian and security crisis. The combination of a suspension of foreign aid, a freeze on Afghan government assets and international sanctions against the Taliban has plunged an already high-poverty country into a widespread economic crisis.

The international community, from governments to non-governmental organizations, has provided various assistance to the Afghan people.


Read also : President Kovind attends celebrations marking 50 years of the liberation of Bangladesh from Pakistan


Subscribe to our channels on YouTube and Telegram

Why the news media is in crisis and how to fix it

India needs free, fair, uninhibited and interrogative journalism even more as it faces multiple crises.

But the news media are in a crisis of their own. There have been brutal layoffs and pay cuts. The best of journalism is shrinking, giving in to crass spectacle in prime time.

ThePrint employs the best young reporters, columnists and editors. To maintain journalism of this quality, it takes smart, thoughtful people like you to pay the price. Whether you live in India or abroad, you can do it here.

Support our journalism

read more
Generic drugs

Generic drugs: are they on par with more expensive brands?

Animation: Farah Hamade

In the United States, more than three-quarters of prescriptions are for generic drugs, non-branded drugs that can cost less than half of their branded counterparts. Generic drugs saved Americans and our health care system over $ 300 billion in 2019 alone.

The use of generics has more than doubled over the past decade, thanks to legislation favoring the production of generic drugs and the expiration of patents on widely used drugs. Despite this enormous growth, myths about the quality of generics persist. The drug safety experts at UCSF help us understand what is the same and what is different, and whether the brand should affect your choices.


MYTH # 1:

Generic drugs are second-rate fakes.

Non-branded products like spaghetti sauce or facial tissues often have a reputation for being worse – they may taste poor or be less durable than the products they imitate. Consumers sometimes associate generic drugs with second-rate fakes because of their lower prices; there is even skepticism among some suppliers.

It is time to get rid of this lingering myth once and for all. Generic drugs are not like other non-branded products, explains Candy Tsourounis, PharmD, professor of clinical pharmacy. They are in their own highly controlled category.

The myth of poor quality can be reinforced by the look, feel or taste of generics compared to brand name drugs that consumers are familiar with. This is because the inactive fillers, coatings, or liquids that help release the active ingredient – the drug itself – can vary.

“A lot of people see generics as somehow inferior due to observable differences,” says Tsourounis, as generics manufacturers modify these inactive components. It also explains why brand-name over-the-counter treatments like headache or allergy medications are different from over-the-counter generics. “For example, the brand name can be a tablet with a glossy coating that tastes good and lowers easily, while the generic can be a chalky white pill with a bitter aftertaste.”

“These differences exist, but the pharmacology – how the drug works in the body, the drug it contains and how long it takes to get to where it needs to be in the body – is the same,” explains Tsourounis, who oversees The UCSF Health Drug Formulary, the list of safe and effective drugs approved for use in the institution. “These are the most critical pieces,” she says. “The rest is just aesthetic.”


MYTH # 2:

Generic testing is not that rigorous.

Generic drugs don’t go through the same testing protocols as brand-name drugs, but there’s a good reason, explains Tsourounis.

“It’s not that the tests are less rigorous, but it’s different,” she says. It takes eight to 12 years of research and development, including clinical trials, to make sure a new drug is safe and effective. All the steps involved in bringing a drug to the market represent significant costs for the company holding the patent.

However, generics are not new drugs. When the patent becomes available on an existing approved drug, a generic manufacturer simply purchases or produces the already developed, tested and approved active component and formulates it into a tablet, capsule or other delivery vehicle. “This timeline is month, not years, ”says Tsourounis, so it costs a lot less to bring a generic drug to the market. When multiple manufacturers produce the same generic drug, competition drives prices down further.

The FDA requires that generics contain the same active ingredient as the branded version, have the same strength and format (such as a tablet or capsule), and use the same route of administration (such as by mouth or injection. ). To prove that their formulations work like the original drug, generic manufacturers must meet strict bioequivalence requirements, which means that the drug must be absorbed by the body and measurable in the blood at comparable levels, in a strict range, to those of the brand. drug name.

Tsourounis also points out that FDA regulations govern every detail of pharmaceutical manufacturing, from laboratory facilities to the training required for people who handle and package drugs.

Shalini Lynch, PharmD ’92, associate professor of clinical pharmacy, co-authored a study that found that generic drug skepticism is higher among auxiliary providers like nurses and medical assistants, who receive limited training in pharmacology, than among doctors. “Additional training on specific concepts such as bioequivalence,” explains Lynch, “could… promote a better understanding of the generic approval process.”


MYTH # 3:

Generics just don’t work as well as brand name drugs.

Especially when people switch from a brand name drug to a generic drug, they can experience modest changes. Tsourouni says to avoid jumping to the conclusion that the credits don’t measure up.

“There is a lot to assess before concluding that the generic drug does not work as well as the brand,” she says. Are there interactions with food or other drugs that affect the way the drug is absorbed? Does the person take the medicine at the same time each day? When she hears complaints that a drug didn’t work as quickly or caused a side effect, “there is usually no pharmacological reason for these effects, so I turn to other causes or maybe. even be a placebo effect based on these myths that generics aren’t as good, ”she said.

Pharmacies stock both generics classified as AB – drugs with the highest bioequivalence ratings – and drugs classified as B, which still meet strict FDA requirements but have slightly lower bioequivalence. Generics classified as B may be better suited for the initial use of a drug rather than replacing a branded version. While Lynch warns that additional monitoring may be needed for patients with conditions where small changes in blood levels could pose “immediate and serious risks,” she says the warning is about the situations and risks individual, not drug classes. Lynch and Tsourounis say that it is beneficial for all patients to discuss generic drug options with their doctor.

“The bottom line is that generic drugs provide the same active ingredient as the brand at a lower cost, and they should be used whenever appropriate,” Tsourounis explains. “These are good drugs. “

read more
Medical supplies

Help Liberia now donates two of three containers of medical supplies to the Ministry of Health

Congo-City – A non-profit organization, Help Liberia Now, presented the government through the Ministry of Health with two containers of three medical devices which will be distributed throughout the country.

Two of the three containers that are filled with beds, scrubs, PPE, including other useful medical supplies, will currently be distributed to nine of the 15 counties.

Speaking in an interview with reporters at the Ministry of Health headquarters in Congo Town, the executive director of Help Liberia Now, Amb. Ebenezer Norman, said they were able to engage other organizations, philanthropic and mainly prominent Liberians at home and abroad.

According to Norman, the commitments have resulted in the signing of an agreement with Project CURE to send three containers worth $ 1,000,000 to Liberia, but only two are currently in the country with the last month scheduled for January. 2022.

He added that funding for the purchase of medical supplies was provided by Colorado State Representative Nequetta Ricks and hosts of other prominent Liberians, including Senators Abraham Dillon, Nyonblee Karnga-Lawrence and Henry. Costa, saying Montserrado County Senator Saah H. Joseph was instrumental in the process.

said amb. Norman, “This is the result of the efforts of a few Liberians from all walks of life who have decided to help their country. Colorado District 40 Representative Nequetta Ricks was a big part of making this happen. “

“There are simple things we can do to make life better here. There are simple things that are missing in our healthcare industry and these are things we can contribute to. “

Amb. Norman revealed that the arrival of these supplies is the start of organizing many of the upcoming commitments, adding, “The only way to improve is to give hope to our people.”

Also speaking, Help Liberia Now Country Director Mr. William T. Thompson, II said the organization’s goal is to ensure that Liberia is not severely affected by the virus as this was the case in the case of Ebola.

Mr Thompson said that as they try to improve the government’s efforts in the health sector, they will immediately start sending their team who will distribute the supplies to the nine counties to which the roads are accessible.

“We will begin distributing to the remaining counties during the dry season,” Thompson revealed.

On receiving the medical supplies, the Minister of Health, the Hon. Dr Wilhelmina Jallah congratulated the organization for its support to the health sector.

Minister Jallah explained that the distribution team will ensure that the donated items are used for the intended purpose and for the legitimate group of people.

“It is not a privilege, but an honor to receive this, and I hope they are used to the people in the counties so that the donors can have good comments,” she said.

read more
Medical supplies

Global group donates thousands of dollars in medical supplies to West Kentucky

Thousands of dollars in medical supplies are headed west Kentucky. OS International has donated $ 15,000 worth of items like wheelchairs and canes, which may have been lost or destroyed by tornadoes The Red Cross collected the donations on Tuesday morning. The president and CEO of the organization tells WLKY it is important for groups to work together to make a difference when these kinds of natural disasters strike. produce. “Sometimes you have to find the right partner. We weren’t just going to load our truck up and drive them there,” said CEO Denise Sears. “You want to make sure that you provide the number of items needed. That you have a partner on the ground who will deploy them to people in need.” warehouse in Paducah, where they will be distributed to tornado victims in western Kentucky. OS is working around the world to salvage and redistribute excess medical supplies. Click here to learn more about the organization and how to help.

Thousands of dollars in medical supplies are heading west Kentucky.

SOS International donated $ 15,000 worth of items like wheelchairs and canes, which may have been lost or destroyed by tornadoes last weekend.

The Red Cross collected the donations on Tuesday morning.

The organization’s president and CEO tells WLKY it’s important that groups work together to make a difference when these kinds of natural disasters happen.

“Sometimes you have to find the right partner. We weren’t just going to load our truck up and drive it over there,” said CEO Denise Sears. “You want to make sure that you provide the number of items you need. That you have a partner on the ground who will deploy them to people in need. “

The supplies are headed to the Red Cross temporary warehouse in Paducah, where they will be distributed to victims of the tornado in western Kentucky.

SOS works around the world to collect and redistribute surplus medical supplies.

Click here to learn more about the organization and how to help.

read more
Medical supplies

Henry Schein’s new contract (HSIC) expands medical supplies arm

Henry Schein, Inc. HSIC recently entered into a cooperation contract with OMNIA Partners to expand into the field of point-of-care testing, personal protective equipment (PPE) and essential medical supplies. OMNIA Partners is considered the country’s largest purchasing organization for public and private markets.

The partnership is expected to expand Henry Schein’s access to the aforementioned fields in academia and public health. However, the financial terms of the deal were not disclosed.

Details of the agreement

Henry Schein has indicated that the product and supplies from this partnership will be available through Henry Schein Medical University Health. The company has entered into a master distribution agreement with the University of California. This framework agreement covers the distribution of medical supplies to the University of California and all eligible public organizations registered with OMNIA partners.

According to Henry Schein, this framework agreement will help increase savings and support, and provide easy access to COVID-19 testing and services. This will therefore help the company to better serve its “medical” customers involved in university health, K-12 education, local and national government health care, and first aid services. In addition, this master agreement will also offer supplies of medical products, laboratory, treatment room and equipment, pharmaceuticals, vaccines, influenza, education, training and simulation to help meet the challenges. needs of student health centers, physiotherapy, occupational therapy, sports clients in medicine, sports training, laboratory and pharmacy.

Strategic importance

According to Henry Schein, this cooperation contract with OMNIA Partners will help streamline the procurement process for the company’s clients within its medical wing. This collaboration aims to help HSIC customers gain comprehensive options for purchasing the medical products and supplies they need to maintain the health and well-being of the public, as well as students and staff.

Image source: Zacks Investment Research

Additional benefits of this contract include support from sales and service specialists, and expanded access to Henry Schein Medical’s product portfolio.

Recent notable developments

In December 2021, Henry Schein’s orthodontic company, Henry Schein Orthodontics, released Studio Pro 4.0, an online treatment planning software for Reveal Clear Aligners. Reveal is the clear solution that helps clinicians meet their patients’ requests for transparent aligners. It features direct integrations with many leading intraoral scanners as well as direct connections with practice management software. Henry Schein Orthodontics supplies a variety of orthodontic products to dental markets around the world.

In June 2021, Henry Schein entered into a $ 53.4 million nationwide storage contract with the US Department of Health and Human Services (HHS). The terms of the contract require the company to provide storage and innovative logistical support for 80,000 pallets of personal protective equipment (PPE) and COVID-related products to healthcare professionals.

In May 2021, the company acquired a 70% stake in eAssist Dental Solutions (eAssist). This acquisition will help the company fulfill its mission of providing cutting-edge solutions that help dental practices operate more efficiently and cost effectively, allowing them to focus more on patient care.

Share price return

The stock has underperformed its industry over the past year. It increased by 9% compared to the industry growth of 13.5%

Rank of Zacks and choice of keys

Henry Schein currently wears a Zacks Rank # 3 (Hold).

Some better classified actions of the wider medical space are Chemed Company CHE, Corporation of America Holdings Laboratory, Where LabCorp LH and Medpace Holdings, Inc. MEDP.

Chemed has a long-term profit growth rate of 7.7%. The company has beaten earnings estimates in three of the past four quarters and missed one, delivering a surprise of 5.6% on average. He currently wears a Zacks Rank # 2 (Buy).

Chemed has outperformed its industry over the past year. CHE gained 3.7% against a drop of 35.6% for the industry.

LabCorp announced third quarter 2021 adjusted EPS of $ 6.82, beating Zacks’ consensus estimate by 42.9%. Revenue of $ 4.06 billion was 13.4% higher than Zacks’ consensus estimate. He currently wears a Zacks Rank # 2. You can see the full list of Zacks # 1 Rank (Strong Buy) stocks today here.

LabCorp has an estimated long-term growth rate of 10.6%. LH has beaten estimates over the past four quarters with an average surprise of 25.7%.

Medpace announced third quarter 2021 adjusted EPS of $ 1.29, beating Zacks’ consensus estimate by 20.6%. Revenue of $ 295.57 million was 1.2% higher than Zacks’ consensus estimate. He currently wears a Zacks Rank # 1.

Medpace has an estimated long-term growth rate of 16.4%. The MEDP has beaten estimates over the past four quarters, with an average surprise of 11.9%.

Boom in infrastructure stocks will sweep America

A massive push to rebuild crumbling American infrastructure will soon be underway. It is bipartisan, urgent and inevitable. Billions will be spent. Fortunes will be made.

The only question is, “Are you going to jump into good stocks early when they have the greatest potential for growth?” “

Zacks published a special report to help you do just that, and today it’s free. Discover 5 special companies looking to make the most of the construction and repair of roads, bridges and buildings, as well as transporting goods and transforming energy on an almost unimaginable scale.

Download FREE: How to Profit from Billions of Dollars in Infrastructure Spending >>

Click to get this free report

Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report

Henry Schein, Inc. (HSIC): Free Stock Analysis Report

Chemed Corporation (CHE): free share analysis report

Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks investment research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

read more
Prescription drugs

Study: Consumption of Cannabis with Prescription Drugs Could Raise “Significant Risk of Harmful Drug Interactions”

Metabolites in the blood of users appear to interfere with the metabolism of a wide range of prescribed drugs and could lead to toxicity or accidental overdose.

Content of the article

Researchers at Washington State University report that cannabis users who have also used other drugs to treat various conditions may reduce the effectiveness of those drugs.

Advertising

Content of the article

Investigators looking to determine possible drug interactions have found that the positive effects of the treatment drugs taken may decrease or that their negative effects may increase, explains a statement from the university.

If too much medicine builds up in the body, it could cause “unintended side effects such as toxicity or accidental overdose,” the researchers say.

  1. These are the first exemptions from the Controlled Drugs and Substances Act granted for mental health reasons by the new Minister of Health, Jean-Yves Duclos.  PHOTO BY REUTERS / BLAIR GABLE

    Exclusive: Three Canadians With Mental Disorders Have Legal Access To Psilocybin Mushrooms

  2. FILE: Military march organized in Canada after the body of a fallen soldier was repatriated in September 2009.

    Canadian poll: Anxiety or stress are the top reasons Canadian veterans report turning to medical cannabis

  3. A comparison of the exposed and control groups revealed that the former, immediately after the exposure period, had a decrease in sperm motility.  /

    Study: Exposure to cannabis vapors negatively affects mouse semen for two generations

To arrive at this point of view, investigators looked at cannabinoids – including THC, CBD, and CBN – and their major metabolites found in the blood of cannabis users. They used manipulated human kidney cells, allowing them to “examine one enzyme at a time.”

Advertising

Content of the article

According to the university’s statement, the researchers suggest that these cannabinoids and metabolites “interfere with two families of enzymes that help metabolize a wide range of drugs prescribed for various conditions.”

Possible toxicity is a real concern and something doctors should have on their radar, notes lead author Philip Lazarus.

This is especially the case when cannabis is used medicinally, suggests Lazarus. “It’s one thing if you’re young and healthy and smoke cannabis every now and then, but for older people who are on medication, taking CBD or medicinal marijuana can have a negative impact on their health. treatment, ”he warns.

The results are based on two studies published in Metabolism and elimination of drugs: one focused on the cytochrome P450 (CYP) family of enzymes, and the other on the UDP-glucuronosyltransferases (UGT) family of enzymes.

Advertising

Content of the article

“Together, these two families of enzymes help metabolize and eliminate from the body more than 70% of the most commonly used drugs,” the statement said.

Specifically, the researchers found that “cannabinoids and the major metabolites of THC strongly inhibited several CYP enzymes” and that “THC-COO-Gluc appears to play a major role in inhibiting several key enzymes in the liver.”

Regarding UGTs, the three aforementioned cannabinoids – but especially CBD – “inhibited two of the main UGT enzymes found in the liver. CBD was also found to block three enzymes that make up about 95% of UGT’s renal metabolism, which helps flush toxins and certain drugs from the body, ”the release notes.

“If you have kidney disease or if you take one or more drugs that are mainly metabolized by the kidneys and you also smoke marijuana, you may be inhibiting normal kidney function and this may have long term effects on your kidneys. you ”Lazarus warns.

Advertising

Content of the article

Possible toxicity is a real concern and something doctors should have on their radar.  /
Possible toxicity is a real concern and something doctors should have on their radar. / Photo by Getty Images

Calling the results the first to show the inhibitory potential of THC-COO-Gluc – the most abundant cannabinoid metabolite in plasma – researchers write in one of the studies that “the main cannabinoids and their metabolites present in the plasma of cannabis users inhibit several P450 enzymes”.

These enzymes “are involved in the synthesis and metabolism of a range of internal and external cellular components”, according to the medical life sciences.

Shamema Nasrin, the study’s first author, claims that the resulting metabolites created when cannabinoids break down in the body can last for up to 14 days and are in higher concentrations than cannabinoids. These are points, argues Nasrin, that “have been overlooked in previous studies, so we thought we should focus on these as well.”

Advertising

Content of the article

The study authors cite the legalization of cannabis in many parts of the United States and other countries as stressing the “need for a more complete understanding of the constituents of cannabis and their potential for drug interactions.”

As such, the university statement emphasizes that “it is important to be careful when using cannabis with other prescription drugs.”

“Taking CBD or marijuana may relieve your pain, but could make the other medicine you are taking more toxic, and this increase in toxicity may mean that you cannot continue taking this medicine,” says Nasrin.

“So there could be serious ramifications for anticancer drugs, and this is just one example of the many drugs that could potentially be affected by the cannabinoid-enzyme interactions that we are seeing,” she adds.

Authors of an Australian study exploring potential drug interactions with medicinal marijuana would likely agree. “Care should be taken to closely monitor the reactions of cannabis users to certain drugs to ensure their safety, especially for the elderly and those with chronic diseases or kidney and liver disease.” write the authors of the study published in 2019.

A see again in the Journal of the Canadian Medical Association last year there was an increase in the clearance of certain drugs among regular cannabis users. However, “no effects from occasional use have been reported.”

Advertising

Content of the article

We apologize, but this video failed to load.

To subscribe to Weekend dispensary , a new weekly newsletter from The GrowthOp.

Advertising

comments

Postmedia is committed to maintaining a vibrant but civil discussion forum and encourages all readers to share their views on our articles. Comments may take up to an hour of moderation before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications. You will now receive an email if you receive a reply to your comment, if there is an update to a comment thread that you follow, or if a user that you follow comments. Visit our Community rules for more information and details on how to adjust your E-mail settings.

read more
Medical supplies

Henry Schein’s New Deal (HSIC) Expands Medical Supplies Arm – December 14, 2021

Henry Schein, Inc. (HSIC Free Report) recently entered into a cooperation contract with OMNIA Partners to expand into the field of point-of-care testing, personal protective equipment (PPE) and essential medical supplies. OMNIA Partners is considered the country’s largest purchasing organization for public and private markets.

The partnership is expected to expand Henry Schein’s access to the aforementioned fields in academia and public health. However, the financial terms of the deal were not disclosed.

Details of the agreement

Henry Schein has indicated that the product and supplies from this partnership will be available through Henry Schein Medical University Health. The company has entered into a master distribution agreement with the University of California. This framework agreement covers the distribution of medical supplies to the University of California and all eligible public organizations registered with OMNIA partners.

According to Henry Schein, this framework agreement will help increase savings and support, and provide easy access to COVID-19 testing and services. This will therefore help the company to better serve its “medical” customers involved in university health, K-12 education, local and national government health care, and first aid services. In addition, this master agreement will also offer supplies of medical products, laboratory, treatment room and equipment, pharmaceuticals, vaccines, influenza, education, training and simulation to help meet the challenges. needs of student health centers, physiotherapy, occupational therapy, sports clients in medicine, sports training, laboratory and pharmacy.

Strategic importance

According to Henry Schein, this cooperation contract with OMNIA Partners will help streamline the procurement process for the company’s clients within its medical wing. This collaboration aims to help HSIC customers gain comprehensive options for purchasing the medical products and supplies they need to maintain the health and well-being of the public, as well as students and staff.

Image source: Zacks Investment Research

Additional benefits of this contract include support from sales and service specialists, and expanded access to Henry Schein Medical’s product portfolio.

Recent notable developments

In December 2021, Henry Schein’s orthodontic company, Henry Schein Orthodontics, released Studio Pro 4.0, an online treatment planning software for Reveal Clear Aligners. Reveal is the clear solution that helps clinicians meet their patients’ requests for transparent aligners. It features direct integrations with many leading intraoral scanners as well as direct connections with practice management software. Henry Schein Orthodontics supplies a variety of orthodontic products to dental markets around the world.

In June 2021, Henry Schein entered into a $ 53.4 million nationwide storage contract with the US Department of Health and Human Services (HHS). The terms of the contract require the company to provide storage and innovative logistical support for 80,000 pallets of personal protective equipment (PPE) and COVID-related products to healthcare professionals.

In May 2021, the company acquired a 70% stake in eAssist Dental Solutions (eAssist). This acquisition will help the company fulfill its mission of providing cutting-edge solutions that help dental practices operate more efficiently and cost effectively, allowing them to focus more on patient care.

Share price return

The stock has underperformed its industry over the past year. It increased by 9% compared to the industry growth of 13.5%

Rank of Zacks and choice of keys

Henry Schein currently wears a Zacks Rank # 3 (Hold).

Some better classified actions of the wider medical space are Chemed Company (CHE Free report), Corporation of America Holdings Laboratory, Where LabCorp (LH Free report) and Medpace Holdings, Inc. (MEDP Free report).

Chemed has a long-term profit growth rate of 7.7%. The company has beaten earnings estimates in three of the past four quarters and missed one, delivering a surprise of 5.6% on average. He currently wears a Zacks Rank # 2 (Buy).

Chemed has outperformed its industry over the past year. CHE gained 3.7% against a drop of 35.6% for the industry.

LabCorp announced third quarter 2021 adjusted EPS of $ 6.82, beating Zacks’ consensus estimate by 42.9%. Revenue of $ 4.06 billion was 13.4% higher than Zacks’ consensus estimate. He currently wears a Zacks Rank # 2. You can see the full list of Zacks # 1 Rank (Strong Buy) stocks today here.

LabCorp has an estimated long-term growth rate of 10.6%. LH has beaten estimates over the past four quarters with an average surprise of 25.7%.

Medpace announced third quarter 2021 adjusted EPS of $ 1.29, beating Zacks’ consensus estimate by 20.6%. Revenue of $ 295.57 million was 1.2% higher than Zacks’ consensus estimate. He currently wears a Zacks Rank # 1.

Medpace has an estimated long-term growth rate of 16.4%. The MEDP has beaten estimates over the past four quarters, with an average surprise of 11.9%.

read more
Prescription drugs

Hyperlipidemia Prescription Drug Market Outlook to 2026 by Application, End User and Geography

The latest research report on Prescription Drug Market for Hyperlipidemia Informs the reader of all the important aspects that influence the behavior of the industry, such as the main growth drivers and challenges, to enable stakeholders to make informed decisions for the future. It also includes a comparison of past and current business scenarios to support the study’s forecast. In addition, the document offers a detailed account of the various market segments and recognizes the key areas that promise solid revenues in the years to come.

According to industry experts, the hyperlipidemia prescription drug market size is expected to yield high profits over the period 2021-2026, registering a XX% CAGR throughout.

Research literature uncovers the impact of the COVID-19 pandemic on this area, with a focus on barriers such as changes in customer behavior, supply chain flows, and imbalances in business operations . It also recommends various approaches that will ensure an upward growth trajectory in the years to come.

Request a copy of this report @ https://www.nwdiamondnotes.com/request-sample/100872

ImportantPointers of the Hyperlipidemia Prescription Drugs Market report:

  • COVID-19 Status and Its Impact on Industry Compensation
  • Market and submarkets growth rate approximations
  • Predominant trends in the vertical
  • Business expansion opportunities
  • Advantages and disadvantages of the indirect and direct sales channel
  • Main traders, suppliers and resellers

Hyperlipidemia Drugs Market Segments Covered in Report:

Geographic bifurcation: North America, Europe, Asia-Pacific, South America and Middle East & Africa

  • Review of the business landscape for each regional market at country level
  • Aggregate sales and revenue data for each area
  • Share of industry captured by major regional contributors
  • Estimates of the growth rate of each regional market over the evaluation period

Product Types: HMG COA Reductase Inhibitors, Fibric Acid Derivatives, Nicotinic Acid, Bile Acid Sequestering Agents, Cholesterol Absorption Inhibitors, and Combination Drug Therapy

  • Sales, revenue and market share of each product segment
  • The pricing model for each product category

Application spectrum: Hospital and Clinic

  • Global turnover and sales secured by each application segment
  • Product pricing according to scope

Competitive dashboard:

  • Amgen
  • Eli lilly
  • GlaxoSmithKline Pharmaceuticals
  • Isis Pharma
  • Merck
  • Dr Reddy’s laboratories
  • Immuron Limited
  • Esperion Therapeutics
  • Pfizer and Formac Pharma

  • Products and services offered by the best companies
  • Leading organizations manufacturing facilities in the geographies served
  • Annals of price models, gross margins, sales, market share and cumulative revenue of major players
  • SWOT analysis of the main organizations
  • New emerging competitors in the market
  • Review of well-known trading tactics
  • Conclusive overview of market concentration rate and commercialization rate

Purpose of Prescription Drugs for Hyperlipidemia: –

To assess the value, market share, sales margin, hyperlipidemia drugs industry status (2016-2020) and forecast scenario (2021-2026).

To study the main players of the drug Hyperlipidemia and their company profiles, their statistics of production, consumption and import-export

To analyze the growth, opportunity, development, and risk of the Hyperlipidemia Drugs industry in various regions.

To understand the competitive view of the market, SWOT and gross margin statistics.

To present, describe, analyze, and define the Hyperlipidemia Drugs industry on the basis of product type, applications, and regions.

To examine development plans, industry policies, market size, value, and sales of major players in Hyperlipidemia Prescription Drugs.

Investigate crucial factors such as market risks, drivers, maturity analysis of prescription hyperlipidemia drugs.

Table of contents overview:

  1. Hyperlipidemia Prescription Drug Market Overview
  2. Hyperlipidemia Prescription Drug Market Company Profiles
  3. Competition in the market, by players
  4. Market Size Segment by Type
  5. Market Size Segment by Application
  6. North America by Country, Type and Application
  7. Europe by country, type and application
  8. Asia-Pacific by Region, Type and Application
  9. South America by Country, Type and Application
  10. Middle East & Africa by Country, Type and Application
  11. Research results and conclusion.

Request customization on this report @ https://www.nwdiamondnotes.com/request-for-customization/100872

read more
Prescription drugs

Florida man admits selling mislabeled prescription drugs to infiltrate Lubbock DEA agent | KLBK | KAMC

LUBBOCK, Texas – A Florida man admitted on Monday to selling mislabeled prescription drugs to an undercover Lubbock Drug Enforcement Administration agent, court records showed. The admission was part of a plea agreement.

Albert Richard Boozer, of Palm Beach, Florida, was first contacted by an undercover DEA agent in Lubbock in late 2019, court documents show.

Court documents say the officer contacted a suspected drug dealer and attempted to purchase 200 Adderall pills for $ 800. The trafficker agreed and the agent wired the money and provided a PO box where the trafficker could send the drugs.

In February 2020, an envelope arrived with a bottle of the “Super Flex-6” dietary supplement, according to court documents. Inside the bottle were 192 pink circular tablets, which contained tramadol, a controlled narcotic.

Court documents said later in the month that another envelope arrived at the secret post office box. It contained a smaller bubble envelope containing 101 pink tablets. A lab report said the package contained 97 tramadol tablets.

While the packages were sent by “Ryan Smith,” Boozer was identified through a Stamps.com account he was using to ship the drugs, according to court documents.

When investigators obtained a warrant to search his emails, they found several messages regarding the reshipment of prescription drugs for a company in India. Investigators also found several food supplement pill bottles containing pills when they collected garbage from her home. The pills were found to be controlled substances, according to court documents.

On Monday, the guilty plea had not been accepted by a judge.

read more
Prescription drugs

Is mixing cannabis and prescription drugs a good idea?

It is well known that cannabis has many medicinal benefits, including the management of chronic pain, epilepsy, anxiety, and the treatment of symptoms of PTSD.

However, in the case of cannabinoids, a group of substances found in the cannabis plant, there is a risk that its combination with other prescription drugs could lead to harmful drug interactions, new research from scientists at Washington State University (WSU) has suggested. .

Researchers looked at cannabinoids and their main metabolites found in the blood of cannabis users and found that they interfere with two families of enzymes that help metabolize a wide range of drugs prescribed for various conditions. As a result, either the positive effects of the drugs might decrease, or their negative effects might increase with too much accumulation in the body, causing unintended side effects such as toxicity or accidental overdose.

The results examined the interaction between three of the most abundant cannabinoids – tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN).

While more research is essential, the authors suggested using caution when using cannabis with prescription drugs.

“Physicians should be aware of the possibility of toxicity or a lack of response when patients use cannabinoids,” said Philippe Lazare, lead author of the article and Boeing Distinguished Professor of Pharmaceutical Sciences. “It’s one thing if you’re young and healthy and smoke cannabis every now and then, but for older people who are on medication, taking CBD or medicinal marijuana can have a negative impact on their health. processing. “

Lazarus added, “It’s one thing if you’re young and healthy and smoke cannabis every now and then, but for older people who are on medication, taking CBD or medicinal marijuana can have a negative impact. negative impact on their treatment. “

The results

The researchers used manipulated human kidney cells and confirmed their results in human liver and kidney samples in which enzymes were present.

Shamema nasrin, a graduate student from WSU College of Pharmacy and Pharmaceutical Sciences, pointed out that even though cannabinoids remain in the consumer’s body for about 30 minutes before being quickly broken down, the metabolites resulting from this process could remain in the system for up to 14 days.

What’s more, the metabolites are also found “in higher concentrations than cannabinoids,” she explained, adding that they had been “overlooked in previous studies.”

Potential negative drug interactions include a decrease in the positive effects of the drugs, as well as an increase in its negative effects resulting in excessive build-up in the body which could cause unintended side effects such as toxicity or accidental overdose.

“Taking CBD or marijuana might ease your pain, but could make the other drug you’re taking more toxic, and this increase in toxicity may mean you can’t keep taking this drug,” Nasrin said. “So there could be serious ramifications for anticancer drugs, and this is just one example of the many drugs that could potentially be affected by the cannabinoid-enzyme interactions that we are seeing.”

Authorities in Virginia Highlight Potential of Psychedelics in Treating Depression and PTSD

What happens if you smoke weed every day?

Photo: Courtesy of Talha Hassan to Unsplash

read more
Medical supplies

How Medpick simplifies the process of purchasing medical supplies

In 2016, when Dr Ranjit Makam’s father survived a stroke, he realized that although he lives in one of the main cities with the latest medical facilities, it often becomes difficult for caregivers. to obtain medical supplies. Medpick was originally formed as a Bengaluru-based healthcare startup that worked as a B2C supplier of drugs and medical equipment.

Digging deeper, Ranjit realized that the loopholes created – procurement processes leading to lost revenue and inefficient patient care – were for B2B players like retail pharmacies and medical stores. Thus, Medpick decided to tackle the problem of providing appropriate medical supplies to retail stores and now operates as a B2B platform to simplify the procurement of drugs in healthcare companies.

Facilitate easy pharmaceutical delivery

Since there were only a few names in the business when Medpick started, it was easier to create the startup where a group of like-minded people with the same medical background came together to solve the problem on the platform.

Commenting on his current services, Chethan KS, Co-Founder and Biomedical Engineer at Medpick, said, “As a B2B platform, we face customers from both sides. While on the one hand, Medpick helps hospitals, small clinics, government projects, and laboratories automate procurement, maintain medical supplies, and acquire products overseas, it also lends a helping hand. white-level medical suppliers and distributors in marketing their products to achieve a uniform sales flow, when regional marketing can be a major obstacle. In addition, Medpick also serves as a platform to organize its supply chain, while reaching out to new hospitals across the country. In conclusion, Medpick is the meeting point for hospitals and medical providers, which ultimately benefits customers.

Solarix deserves special mention here, especially at a time when the world is gripped by the pandemic. Chethan adds, “Solarix is ​​a portable disinfectant device that appears to be tailor-made for the Indian market. Originally designed and manufactured in Canada, Solarix was introduced to Medpick by one of its vendors. Perhaps Solarix was also the means of opening the doors to the supply of drugs from Canada to Indian hospitals, thus increasing the visibility of the market. So, Medpick enabled Solarix on its app, and apart from medical organizations, it also reached end users from whom taxi drivers have greatly benefited, helping them disinfect the surface, decreasing fear of contamination.

Medpick deals with a wide variety of health insurance businesses. The most important thing for Chethan is to help hospitals / medical organizations obtain imaging equipment, whether for MRIs, X-rays or ultrasounds. Often times, it becomes difficult for hospitals to pay for imaging machines. Medpick helps them get refurbished equipment from the United States.

Recent statistics show that hospitals that source through Medpick have already reduced their procurement costs by 10-15%. Additionally, all of the large slides and medical equipment that have been parked in warehouses due to lack of proper maintenance have been made operational by Medpick based on their excellent biomedical network spread across the country.

The e-commerce platform allows doctors to instantly decide on the purchase of a product with detailed specifications, as well as import equipment for hospitals around the world, use improved medical technologies for the India, and also to help healthcare startups follow the right marketing strategies for their products.

Ease and affordability of a .in domain

Considering their potential customers, Medpick generally works offline. So, to educate them on the benefits of buying online, the .in domain has served well. Catering to hospitals and manufacturers across India was our main focus when we launched the e-commerce store. The .in domain seemed like a natural way to scale up, ”says Chethan.

The National Internet Exchange for India (NIXI) helps many businesses across the country obtain a .in or .Bharat domain. Businesses of any scale and size can benefit from a .in domain with the help of NIXI. It is affordable and can be used in over 22 languages ​​for businesses from all parts of the country.

Growth and turnover

Medpick realized that their true calling was to refurbish, operate, and supply medical devices to hospitals. Tracing the history of growth, Medpick began by integrating a single multi-specialty hospital, from which it reached over 100 hospitals, contacting the platform daily through their app or website. In addition, they have successfully partnered over 150 manufacturers and distributors across India, expanding to a wider space regardless of location.

With the restrictions brought about by the pandemic, most hospitals are restricting the entry of medical representatives, increasing the difficulties for manufacturers and distributors to market their products. Chethan sees this as a golden opportunity for Medpick as they can help hospitals move their medical shopping online while helping suppliers and manufacturers move their supply chain online.

Commenting on the future roadmap, Chethan said, “We see a good market opportunity through our GPO-based purchases, leading to at least 500 hospital purchases by next fiscal year, as well as the projection. from 500 to 600 manufacturers. “

The series “Shaping India Inc’s Online Growth” chronicles the journeys of startups and SMEs in India and how the creation of an online presence in the .in or .Bharat domain has fueled their successes.


read more
Generic drugs

Generics and biosimilars get last-minute stay of rebates with Senate adjustments for Build Back Better Act – Endpoints News

The Senate Finance Committee on Saturday released the latest text of President Joe Biden’s $ 2 trillion spending plan, paid at least in part with new bargaining power for Medicare and inflation discounts that manufacturers of drugs will have to pay if their drug prices rise too quickly each year.

But now generic drugs threatened with shortages and biosimilars have been excluded from discounts, as demanded by their industry lobby groups. They said the inclusion of such discounts and negotiations could increase the likelihood of drug shortages and create barriers to competition.

According to the latest version of the text of the bill, generic Part D drugs that are in short supply may be exempted, as well as biosimilars, and the secretary of the HHS may make certain decisions that a drug may be eligible for a reduction. or a waiver, if access to the drug would be severely reduced.

Unlike Medicaid, under current law Medicare does not have the power to limit annual price increases for drugs covered by Part B or D. Rebuild Better Act would require drugmakers, starting in 2023, to remit the federal government if their prices for single-source drugs and biologics rise faster than the rate of inflation, according to KFF.

Manufacturers who do not pay this discount would be penalized and forced to pay at least 125% of the original discount.

The Congressional Budget Office (before the exclusion of generics and biosimilars) estimated that the net reduction in the federal deficit through rebates would be around $ 84 billion over 10 years (through 2031). The CBO also estimated that about 10 fewer drugs (out of a calculated total of 1,300 drug approvals) over 30 years would not be developed because of the lost money.

Finance Chairman Ron Wyden (D-OR) said in a statement: “Our package is historic. It would create well-paying jobs, lower the cost of raising a family, tackle the climate crisis and lower energy bills, build more affordable housing, and lower health care costs for families and the elderly.

read more
Medical supplies

Hebei contributes to a stable supply of global anti-epidemic medical supplies

Beijing, China, December 12, 2021 (GLOBE NEWSWIRE) – Demand for epidemic prevention equipment has increased again in and abroad since the mutated-Omicron virus. With the aim of alleviating the pandemic situation in the world, the Hebei Epidemic Prevention Medical Supplies Export Online Fair is launched by the Hebei Provincial Department of Commerce from November 2021 to June 2022. The online fair is divided into two parts, the products are displayed in the global online business matching platform www.gbmof.com, which is established by the co-organizer CMEC International Exhibition Co., Ltd. and a meeting of online business matching between buyer and supplier.

Photo available: Hebei medical supplies

The one-to-one online business matchmaking session has already been successfully completed on December 3, 2021. The session lasted 5 days to match potential buyers of medical supplies from countries around the world with suppliers of Hebei’s high-quality epidemic prevention medical supplies via live online chat. The corresponding effect has been highly appreciated by overseas suppliers and buyers.

About 50 Hebei-based suppliers have joined the Online Business Matching. These suppliers specialize in the production of medical equipment and products, such as masks of various specifications, insulation and protective clothing, disposable gloves, infrared thermometer, antibody detection kits, blood concentrator. oxygen, respiratory products, etc. Suppliers provided related product certifications and qualifications when meeting with buyers to prove that all products are covered with good quality. Buyers participating in the online business match come from more than 10 countries, such as Thailand, Vietnam, Malaysia, Singapore, Pakistan, Bangladesh, Russia, Kazakhstan, Brazil, on three continents: Asia , Europe and America. The total number of buyers registered for Online Business Matchmaking is over 80 and the nature of their business includes not only hospitals, clinics, pharmacies, laboratories, but also importers and distributors. On average, each supplier connected with at least five buyers. Most of the suppliers are satisfied with the quality of the buyers. At the same time, the buyers also learned more about the products of the suppliers through the online demonstration in the meetings.

As the main province of epidemic prevention material production, Hebei is actively expanding its capacity in response to epidemic prevention needs around the world. Since this year, the export of epidemic prevention materials to Hebei Province has maintained rapid growth. Taking medical gloves as an example, exports of various medical gloves totaled 8.8 billion yuan in the first half of this year, 2.92 times more. The Hebei government also takes the quality and compliance of epidemic prevention export products very seriously. Take all measures to ensure the quality of the exported anti-epidemic supplies, to improve the quality supervision of the exported medical supplies, including face masks (non-medical use), to guarantee the export order and to allow the export of products meeting quality standards and overseas registration requirements. Hebei will continuously export the high quality epidemic prevention materials and products to overseas market. In addition to continuing to make a positive contribution to the health of people around the world.

The Hebei Outbreak Prevention Medical Supplies Online Fair will last until next June and the fair aspires to be a reliable platform to connect suppliers and buyers around the world by sharing epidemic prevention medical resources. .

If you would like to know more about the event, please click here http://www.gbmof.com/en/exhibitor_sub/21102803. You can also call Ms. Emera at + 86-15810085600 or send an email to [email protected]

http://www.gbmof.com/en/exhibitor_sub/21102803

Emera Zhang

CMEC International Exhibition Co., Ltd

+ 86-15810085600

[email protected]

Main logo

read more
Generic drugs

For pushing generics, Valley set to get 45 more ‘Jan Aushadhi stores’ – Jammu Kashmir Latest news | Tourism

In 2 phases, 50 stores of this type are already operating

Irfan Tramboo

Srinagar, December 12: After setting up around 50 Jan Aushadhi stores in Kashmir, the Ministry of Health has initiated the process of establishing 45 more such stores as part of phase III to ensure that Kashmir patients are getting quality drugs by pushing generic drugs into the market by strengthening the chain of these stores.
Officials told Excelsior that as part of the latest Phase III, the department will establish 45 additional Jan Aushadhi stores across Kashmir under Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) in hospitals that operate around the clock.
Under phase III, 2 other Jan Aushadhi stores will be installed in Srinagar at PHC Zadibal and Khanmoh, 6 at Budgam at CHC Pakharpora, Kremshore, PHC Khag, Poshkar, Surasyar and Hardpanzoo.
In Pulwama district, the department is ready to open 5 Jan Aushadhi stores in PHC Awantipora, Kakpora, Khrew, Litter and Aribal; in Ganderbal, 5 other stores of this type will be installed at MMC Watlar, PHC Tulmulla, NTPHC Gutlibagh, Ganiwan and PHC Wussan.
In Baramulla, the department plans to open 5 stores of this type in PHC Boniyar, Kunzer, Dangiwacha, Tarzoo and Kreeri; in Kupwara, 9 of these stores will be opened in CHC Sogam, Kralpora, Zachaldara, Langate, Kralgund and Villgam, Trejgam, Kalaroose and Chogal.
In Bandipora, 4 other stores of this type will be opened in CHC Dawar, PHC Chuntimulla, Ashtingoo and NTPHC Naidkhai; in Anantnag, in the same way, 3 other stores are planned which will be born in SDH Dooru, PHC Larnoo and NTPHC Pahalgam.
In Shopian 2, such stores were provided at PHC Sedow, DK Pora; at Kulgam 4, such stores will appear at PHC Qaimoh, Qazigund, Mohammad Pora and PHC Nihama.
It should be noted here that the process of creating Jan Aushadhi stores was started in 2019 and as part of phase I of it, 23 stores were created, followed by phase II in which 32 of these stores have been approved. , bringing the total number of Jan Aushadhi stores in Kashmir hospitals to 55, including one in Leh and Kargil.
Previously, the additional chief secretary H&ME had asked officials to increase the number of Jan Aushudi stores across Kashmir, and according to the instructions, the marketing directors were invited to submit the proposals accordingly for the establishment of new stores in their districts.
Officials say the process is currently underway and in a week or so they will have approval for Jan Aushadhi stores under Phase III.
Within the framework of the PMBJP, by creating Jan Aushadhi stores, it aims to guarantee access to quality drugs for all sections of society and at the same time to promote generic drugs.
Nodal Officer Jan Ashudi for the Kashmir Division, Dr Nishat Shaheen told Excelsior that DHSK is currently processing the documents and the process is being carried out according to guidelines.
Interestingly, Jan Aushadhi’s drug prices are 50-90% lower than brand-name drugs on the open market, while the drugs are purchased only from suppliers certified by the World Health Organization. – Good manufacturing practices (OMS-GMP) to ensure product quality. (PTI)

read more
Medical supplies

Hebei contributes to stable global supply of anti-epidemic medical supplies

Content of the article

Beijing, China, 12 Dec. 28, 2021 (GLOBE NEWSWIRE) – Demand for epidemic prevention materials has increased again at home and abroad since the mutation of the Omicron virus. With the wish to alleviate the pandemic situation in the world, Hebei Epidemic Prevention Medical Supplies Online Fair is launched by Hebei Provincial Department of Commerce from November 2021 to June 2022. The online fair is divided into two parties, the products are exhibited in the global business matchmaking online platform www.gbmof.com , which is established by co-organizer CMEC International Exhibition Co., Ltd and an online business matchmaking meeting between buyer and supplier.

Content of the article

Photo available: Hebei medical supplies

The one-on-one online business matching session has already ended successfully on December 3, 2021. The session lasted 5 days to connect potential buyers of medical supplies from countries around the world with Hebei high-quality epidemic prevention medical supplies suppliers via live online chat. The matching effect has been highly appreciated by overseas suppliers and buyers.

About 50 Hebei-based suppliers have joined the online Business Matching. These suppliers specialize in the production of medical equipment and products, such as masks of various specifications, insulation and protective clothing, disposable gloves, infrared thermometer, antibody detection kits, blood concentrator. oxygen, respiratory products, etc. Suppliers provided certifications and related product qualifications in meeting with buyers to prove that all products are covered in good quality. Buyers participating in online business matching come from more than 10 countries, such as Thailand, Vietnam, Malaysia, Singapore, Pakistan, Bangladesh, Russia, Kazakhstan, Brazil, on three continents: Asia, Europe and America. The total number of registered buyers for online business matching is over 80 and the nature of their business includes not only hospitals, clinics, pharmacies, laboratories but also importers and distributors. On average, each supplier connected at least five buyers. Most suppliers are satisfied with the quality of buyers. At the same time, buyers also learned more about suppliers’ products through online demonstration at meetings.

Content of the article

As the leading province for the production of epidemic prevention materials, Hebei is actively expanding its capacity in response to epidemic prevention needs around the world. Since this year, the export of epidemic prevention materials in Hebei Province has maintained rapid growth. Taking medical gloves as an example, the export of various medical gloves totaled 8.8 billion yuan in the first half of this year, up 2.92 times. The Hebei government also takes the quality and compliance of export epidemic prevention products very seriously. Take all measures to ensure the quality of exported anti-epidemic supplies, to improve the quality supervision of exported medical supplies, including face masks (for non-medical use), to ensure the export order and to enable the export of products meeting quality standards and overseas registration requirements. Hebei will continuously export the high-quality epidemic prevention materials and products to overseas markets. In addition to continuing to make a positive contribution to the health of people around the world.

Content of the article

The Hebei Epidemic Prevention Medical Supplies Online Fair will last until next June, and the fair aspires to be a reliable platform to connect suppliers and buyers from all over the world in sharing epidemic prevention medical resources. epidemics.

If you want to know more about the event, click here http://www.gbmof.com/en/exhibitor_sub/21102803. You can also call Ms. Emera at +86-15810085600 or email [email protected]

http://www.gbmof.com/en/exhibitor_sub/21102803

Emera Zhang

CMEC International Exhibition Co., Ltd.

+86-15810085600

[email protected]

main logo

read more
Medical supplies

Pilot stealing medical supplies killed in New Hampshire plane crash

Pilot stealing medical supplies killed in New Hampshire plane crash near airport



>> HE SAID IT WAS LIKE A SONIC BUM. STRONG, VERY STRONG. SH: JO LESLEY CHEETHAM’S HUANDSB WAKED HER AND THEY SEEN FLAMES OUTSIDE THEIR BEDFORD, NEW HAMPSHIRE HOME JUST ACROSS THE MERRIMACK RIVER FROM MANCHESTER-BOSTON REGIONAL AIRPT. OR >> THAT WAS CONCERNING, VERY CONCERNING. I WANT THIS CLOSE TO HOME, YEAH. THIS IS SCY.AR JOSH: THEY SOONLY LEARNED IT WAS A LITTLE PLANE CRASH JUST OUTSIDE THEIR WINDOW THAT ENTERED THE WOODS AND ON THE BANKS OF THE MERRIMACK RIVER JUST AFTER 11:30 LAST NIGHT. HT AUTHORITIES SAY PILOT REPORTED SHORYTL ENGINE FAILURE B CRASH DID NOT REACH RUNY.WA >> THERE WAS A SINGLE APA OCCUPANT IN THE AIRCRTAF WHO DECEASED. JOSH: YOU CAN SEE INVESTIGATORS ON STAGE LOOKING VERY BIG. FORTUNATY ELTHEY HAS HOURS OF DAY TO SEE WHAT HAPPENS WHEN THE PLANE HAS BROKEN DOWN AND, FROM WHAT PEOPLE DESCRIBED, HAS EXPLODED. THIS VIDEO FROM THE OTHER BOTTOM OF THE RIVER AT NIGHT. AS EMERGENCY BOATS RESPONDED IN THE WATER AND CREW ARRIVED FROM, ACROSS THE AREA AS NEHBIGERS NEARBY QUICK TO SEE WHAT HAPPENED. TELLING US IT WAS A PLANE CRASH. JOSH: THE PILOT OF THE TWIN ENGINE TURBO-PROPULATOR HAS BEEN IDENTIFIED AS EMANUEL VOMVOLAKIS, 23, OF LINDEN, MICHIG, A FLYI MNGEDICAL SUPPLIES OF ESSEX COUNTY, NEW JERSEY. >> WE HATE TO SEE LOSS OF LIFE IN ALL KINDS OF SITUATION LIKE THIS AND WE FEEL FOR THE FAMILY. >> THIS IS VERY SAD. ESPECIALLY THIS TIME OF THE YEAR.AR JO: SH THE PHYSICIAN EXAMINER WILL DO AN AUTOPSY TO CONFIRM IDENTIFICATION AND THE NTSISB INVESTIGATION OF CRH.AS IN BEDFORD,

Pilot stealing medical supplies killed in New Hampshire plane crash near airport

The 23-year-old victim said he had engine problems before his plane crashed and caught fire on the banks of the Merrimack River.

The 23-year-old victim said he had engine problems before his plane crashed and caught fire on the banks of the Merrimack River.

read more
Prescription drugs

Does Medicare Cover Prescription Drugs?

TThe good news is that when you are eligible for Medicare, you will also be able to purchase insurance that pays a portion of the costs of your prescription drugs – in many cases, most of the costs. But there are many caveats about Medicare drug coverage and significant variations in coverage and costs between plans.

Original health insurance (parts A and B) does not cover prescription drugs except in special cases (drugs administered during surgery for example). Original Medicare beneficiaries are eligible to purchase prescription drug coverage, called Medicare, Part D, which is sold and administered by private insurers.

More Advantage of Medicare plans, on the other hand, include coverage for prescription drugs.

In both cases, Medicare Part D and Medicare Advantage, it is important to remember that the specific drugs covered vary from plan to plan. The same goes for monthly premiums and other fees. It is therefore beneficial to educate yourself, shop carefully and re-evaluate your choice of package each year.

What Medicare Part D plans cover

Medicare drug plans cover both generic and brand name drugs. All plans cover certain categories of drugs to treat specific conditions. Each plan decides which specific drugs to insure by category.

Each Medicare Part D plan lists the drugs it covers on a formulary, which typically includes both brand name drugs and generic drugs. Forms change, so it is very important to regularly check that your medications are included.

You should also check each plan for restrictions on drug coverage, such as requirements that certain drugs must be approved in advance by the insurer.

If you or your provider thinks that none of the covered medications will adequately treat your condition, you can request a exception.

What you will pay for prescriptions

In addition to Part D premiums, you may be responsible for cost sharing, which may include deductibles, copayments, or coinsurance. Medicare Part D plans set their own premiums.

Part D plan deductibles vary from $ 0 to the maximum allowed, which in 2021 is $ 445 (rising to $ 480 in 2022). Those with higher incomes will pay an additional monthly fee of $ 12.30 to $ 77.10 for Part D in 2021.

Co-payments or coinsurance

Almost all Medicare Part D and Medicare Advantage plans with prescription drug coverage charge a copayment or coinsurance. Buy with care; your costs will vary from plan to plan.

Part D coverage requires you to pay varying prices for different categories of drugs. In general, your cost share will be higher for brand name drugs.

Note that if you delay your Part D registration for too long, you will have to pay a late registration penalty.

How To Compare Medicare Part D Plans

Medicare.gov can help you find a Part D plan that covers your prescriptions and can help you compare your costs under various Medicare Part D and Medicare Advantage plans.

More from NerdWallet

John Rossheim writes for NerdWallet. Email: [email protected]

Does the Medicare article cover prescription drugs? originally appeared on NerdWallet.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

read more
Medical products

Museveni supports planned medical products factory

President Yoweri Museveni welcomes the initiative being considered by a local company Microhaem Scientific and Medical Supplies Limited and its partners to establish a medical diagnostics and pharmaceutical factory in the country.

During his meeting with a delegation from Microhaem Scientifics (MHS) and its business partners on Thursday, December 9 at State House Nakasero, the president assured the group that he was ready to support initiatives to produce diagnostic tools. and human medicines locally in the country. He said such facilities would also benefit regional and continental demand for medicines for human use.

“I should support the partnership. I tell you that there is a huge demand for human drugs in the country, the region and beyond. The demand is not just in Uganda, the issue affects the entire East African region and the continent. It is not only a question of manufacturing but also of answering the question of the strong demand ”, declared President Museveni.

The president observed that the government spends large sums of money to buy human drugs and diagnostic tools abroad. He further noted that by looking at the annual imports into the country, the import of drugs is very large and continues to expand.

Mr Museveni suggested to investors in the planned partnership that if they chose to manufacture drugs in the country, they would be supported by the indigenous raw materials available to master the manufacturing process. He cited the presence of cinchona which was originally found in South America and which is used in the manufacture of quinine, an antimalarial drug.

“Here in Uganda we have many such products which can be obtained from the local green vegetation. If the pharmaceutical manufacturers have the diverse knowledge to manufacture a variety of medical products, it would be much better for the country and for them. [investors] being insured with the market, ” he added.

MHS Head of Delegation and Managing Director Cedric Akwesigye, who led the discussion, pointed out that Microhaem Scientifics Supplies Ltd (MHS), a Ugandan company founded in 2012, is a huge investment aimed at solving the problem. problem of lack of technical support. on medical equipment and the quality of medical supplies in the country.

“In record time, MHS has partnered with government to set up well-established medical laboratories for the Uganda Virus Research Institute (UVRI) and Central Public Health Laboratories (CPHL) at border points from Malaba, Elegu, Mutukula. These labs have dramatically reduced the turnaround time for COVID-19 test results, especially for truck drivers. So far, the company’s medical facilitation capacity has supported 500,000 Covid-19 tests, ”he said.

Mr. Akwesigye also noted that the president’s stewardship has championed the growth of local businesses like MHS to achieve partnership milestones with reputable global companies. He pledged MHS ‘continued strategic investment in addressing the medical and diagnostic needs of the company.

MHS is partnering with Desert Laboratories Inc in the United States to set up a factory to manufacture medical laboratory molecular tests for Covid-19, HIV, and tuberculosis, among others.

read more
Prescription drugs

Pet Prescription Drug Market size, increasing diversity of trends, analysis, future scope analysis with major key industry players by 2026

The primary objective of the Animal Drugs market report is to determine the performance of the industry over the anticipated time frame to help stakeholders to make informed decisions and action plans that will ensure long term success . The document highlights all the factors that favor the growth of this vertical, followed by counter-approaches to the major challenges facing companies. In addition, it includes the changes in this vertical due to the Covid-19 pandemic and highlights the best opportunities for the future.

Key points of the impact assessment of Covid-19:

  • Impact of Covid-19 on the economic scenario on a global scale.
  • Changes in the share of supply and demand.
  • Predictions of the long-term effects of the Covid-19 pandemic on the growth matrix.

An overview of the regional landscape:

  • Geographically, the pet prescription drug market is divided into North America, Europe, Asia-Pacific, South America, Middle East & Africa, Southeast Asia.
  • The contribution of each region to the overall growth of the industry is measured in the study.
  • An analysis of the revenue, sales and growth rate for key regions during the forecast period is also provided.

Request a copy of this report @ https://www.nwdiamondnotes.com/request-sample/96766

Other important takeaways from the Pet Prescription Drugs Market report:

  • The report categorizes the pet prescription drug market product landscape into oral type, smear type, injection type and spray type.
  • Sales and volume share estimates for each product category are provided.
  • The study also highlights the market share, growth rate and production pattern of each type of product over the forecast period.
  • In terms of the scope, the Animal Prescription Drugs market is fragmented into Pets, Livestock, geographically, the detailed production and trade analysis of the following countries is covered in Chapter 4.2, 5: United States, Europe, China, Japan and India.
  • The market share guaranteed by each application segment along with their growth rate forecast is discussed in detail in the report.
  • The main companies that are setting trends in the pet prescription drug market are Ceva Sante Animale, MSD Animal Health, Ourofino Saude Animal, Dechra, Virbac, Boehringer Ingelheim, Vetoquinol, Zoetis, Animalcare Group and Elanco Animal Health.
  • Listed companies are analyzed on the basis of their gross margins, production models, product and service portfolio, pricing model, market compensation and market share.
  • Major competitive trends and their implications for businesses are comprehensively elaborated.
  • Granular industry supply chain analysis, with details of key manufacturers, suppliers and consumers is included.
  • The feasibility study of a new project using several methodologies such as SWOT analysis and Porter’s five forces analysis is provided in the document.

Reasons to access this report:

  • Know the opportunities and plan strategies by having a solid understanding of the investment opportunities in the Animal Prescription Drugs market
  • Identification of key parameters driving investment opportunities in the prescription animal drugs market
  • Facilitate decision making based on solid historical and forecast data
  • Position yourself to make the most of the industry’s growth potential
  • Develop strategies based on the latest reports.
  • Identify key partners and avenues for commercial development
  • Respond to your competitor’s business structure, strategy and outlook
  • Identify the main strengths and weaknesses of important market players

The key questions answered by this report:

  • What will the market size and growth rate be during the forecast year?
  • What are the key factors driving the global pet prescription drugs market?
  • What are the risks and challenges facing the market?
  • Who are the major vendors in the global pet prescription drugs market?
  • What are the trend factors influencing market shares?
  • What are the main results of Porter’s five forces model?
  • What are the global opportunities for expanding the global pet prescription drugs market?

Important point mentioned in the Research report:

  • Market overview, market dynamics, market growth etc. are cited in the report.
  • The power and commercial output of major manufacturers have been mentioned along with the technical data.
  • The study provides historical market data with revenue forecast and forecast from 2020 to 2025.
  • This report is a valuable asset for existing players, new entrants and future investors.

Table of Contents for Market Share by Application, Research Objectives, Market Sections by Type, and Forecast Years Considered:

Pet Prescription Drugs Market Share by Major Players: Here, the analysis of capital, revenues and prices by the company is included along with other sections such as development plans, areas served, products offered by major players, alliance and acquisition. and seat distribution.

Global growth trends: Industry trends, growth rate of major producers, and production analysis are the segments included in this chapter.

Market Size By Application: This segment comprises an analysis of the Animal Prescription Drugs market consumption by Application.

Pet Prescription Drugs Market Size By Type: It includes analysis of product value, utility, market percentage and production market share by type.

Manufacturer profiles: Here, the major players of the global Animal Prescription Drugs Market are studied on the basis of sales area, key products, gross margin, revenue, price, and production.

Animal Medicines Market Value Chain Analysis and Sales Channels: It includes analysis of customers, distributors, market value chain and sales channels.

Market Forecast: This section focuses on production and production value forecast, forecast of key producers by type, application and regions

Request customization on this report @ https://www.nwdiamondnotes.com/request-for-customization/96766

read more
Medical supplies

Used wheelchairs, walkers and other medical supplies find new homes

For William H. Rosenblatt, MD, HS ’90, FW ’91, an “aha” moment came in an email from a wife desperate to get rid of a storage unit full of medical supplies for her husband recently. deceased. She had pallets of bandages, syringes, fluids and other items in perfect condition for her husband’s dialysis, valued at at least $ 10,000. She tried to donate the material, but had no takers.

“They were telling him to throw it out,” said Rosenblatt, professor of anesthesiology and surgery. The woman contacted Rosenblatt through Med-Eq, which he founded several years ago, and begged him to accept the cache. The Med-Eq website lists excess medical supplies from healthcare organizations and links them with nonprofit organizations. The organization only negotiated donations from hospitals and clinics, but Rosenblatt made an exception.

“I said, ‘yeah, we’ll take them,’” Rosenblatt said.

The experience opened Rosenblatt’s eyes. After a loved one dies, families often have everything from hospital beds to wheelchairs that no one will take.

“I would talk to people sometimes, and they were literally in tears,” Rosenblatt said. “They had gone out and bought these supplies, or they had been paid for by Medicare, and nobody wanted them. The vendors had made a sale. They didn’t want them to come back. Hospitals and clinics were concerned about the legal implications of taking the materials. “

In March 2013, Med-Eq’s website, www.med-eq.org, began tracking donated medical supplies and equipment from bereaved families. As with all of its donations, the material is free to federally recognized nonprofits, which in turn send 80 to 90 percent of articles overseas.

Rosenblatt is a veteran of reusing medical supplies. In 1991, he founded the Recovered Medical Equipment for the Developing World (REMEDY), which sends open but unused surgical and other medical supplies to third world countries. At its peak, the group partnered with more than 600 hospitals, he said. Med-Eq was an outgrowth of REMEDY.

Med-Eq’s new program is still in its infancy, listing at most one individual donation per week, but growing. The organization is upgrading its website for ease of individual use, he said. He also plans awareness raising through clergy and brochures distributed by visiting nurse associations.

Priests, ministers and rabbis are particularly effective communicators as they care for bereaved families, Rosenblatt said. Rabbi Herbert N. Brockman of the Mishkan Israel congregation in Hamden, Connecticut, agreed, saying he distributed a Med-Eq pamphlet about once a month. “You go to them, and when you do, you see all this gear,” Brockman said. “I’ll talk to them if they’re interested.” “

Brockman mentioned Med-Eq to Sue Millen of North Haven, Connecticut, and for her it was a godsend. After Millen’s 97-year-old mother-in-law died, the family had two wheelchairs, dressers, walkers, tongs and other medical supplies. Med-Eq partnered Millen with Renewed Life Philippine Mission, who picked up the items from her home and shipped them to the Philippines.

“I was thrilled,” Millen said. “These things are really used by people. They were really grateful to have them.

read more
Prescription drugs

The Incredibly High Price of Prescription Drugs national news


Insulin is a medical wonder, saving the lives of millions of people who would otherwise die of diabetes. It can also be prohibitively expensive, going up to $ 300 a vial for newer versions of the treatment, which patients with diabetes need two to three times per month.

For patients with less common ailments, the sticker shock can be much worse. Do you have a small child with spinal muscular atrophy, a rare genetic condition that weakens muscles, causes movement problems over time and can be fatal? The good news is that the Food and Drug Administration in 2019 approved a drug, Zolgensma, a one-off curative therapy. The bad news is that it costs over $ 2.1 million – and may not be covered by insurance – making it the most expensive drug in the world.

The prices of prescription drugs in America are a constant source of frustration, anger and bewilderment among patient-consumers. Why are some drugs so expensive – and why are some pills significantly more expensive than the same drug sold overseas? Who decides the price of prescription drugs – and how do you make them affordable without stifling the innovation and research that has produced the miracle cures patients enjoy today?

Political cartoons about Congress

Congress is grappling with this problem now, examining provisions of the “Build Better” bill that seek to reduce the burden on consumers by capping the co-payments patients are supposed to cover and annual out-of-pocket expenses in some cases. circumstances. As is is currently written, the measure would allow Medicare to negotiate drug prices – something the government was specifically prohibited from doing when Medicare Part D, the prescription drug benefit for the elderly, was created in 2003.

The new measure would also impose a tax penalty if drug companies raised prices more than inflation, capped insulin co-payments to $ 35 per month, and capped out-of-pocket expenses for the elderly at $ 2,000 for the elderly. drugs covered by Medicare.

Many Democrats have portrayed the battle as a battle between helpless patients and drugmakers chasing dollars. Republicans say efforts to set prices, even in a roundabout way, will discourage the development of the very treatments that save lives.

“The public truly have a love-hate relationship with the pharmaceutical industry. They appreciate and appreciate the role of the pharmaceutical industry” in developing treatments that change and save lives, Mollyann Brodie, Executive Vice President of health research group Kaiser Family Foundation said in a webinar this week. “On the other hand, they also think the industry is too profit-oriented and the profits are too high.”

The industry, represented by the powerful Pharmaceutical Research and Manufacturers of America (PhRMA), certainly has its bogeymen. Chief among them is Martin Shkreli, the so-called “pharmaceutical brother” who sparked anger in 2015 when his company, Turing Pharmaceuticals, increased the price of a life-saving drug, Daraprim, from $ 13.50 to $ 750 per tablet. (Shkreli is in prison for security fraud. Turing and his parent company agreed wednesday to pay $ 40 million to settle a case alleging stealing from patients).

But pharmaceutical companies have also developed critical therapies and groundbreaking research in diseases ranging from cancer to Alzheimer’s disease. They may have saved humanity through the rapid development of vaccines (and a possible new treatment) against the COVID-19 virus.

But why are some drugs so expensive? And what can be done to make therapy more affordable?

The answer is much more complicated than it looks, experts say. And the solutions aren’t as straightforward as viewing the manufacturers as the sole source of the problem.

“Everyone likes to find the bad guys,” says Wayne Winegarden, director of the Center for Medical Economics and Innovation at the Pacific Research Institute. Aside from some known bad actors (like Shkreli), “there is no bad guy here. We have a really bad health care system that incites all kinds of crazy behavior,” Winegarden says.

Drug prices, experts explain, are determined by various players. A manufacturer sets an “introductory price” – which will usually be higher if it is a new treatment or a breakthrough treatment. An intermediary, called the Pharmacy Benefit Manager, then negotiates discounts and rebates with manufacturers for the drug, which they then provide to pharmacies, doctors and hospitals.

But Pharmacy Benefit Managers don’t necessarily pass the discount on to patients, says Leslie Dach, president of the healthcare reform group Protect Our Care. They also don’t reveal how much of the rebate they got, so patients don’t know what the true cost is.

Insurance may very well cover a particular drug, explains Dach. But since the co-payment is based on the original manufacturer’s price – not the lower negotiated cost paid by the Pharmacy Benefit Manager – the patient ends up paying more.

“Everything here is a black box,” he says.

Pharmacies are also at an impasse, says Douglas Hoey, CEO of the National Community Pharmacists Association. Pharmacy Benefit Managers – three of whom, he says, control 80% of the market – are “incredibly powerful with health care providers.” Intermediary companies can, for example, refer patients to pharmacies in the network and say to pharmacies: “If you do not take our prices, we will refer this patient elsewhere”.

This means that even when the initial cost of a drug goes down, a patient may not see the benefit. A report by Milliman, commissioned and released this week by PhRMA, found that the net price of insulin in 2021 was, on average, 84% lower than the list price due to discounts, rebates and other payments. But experts note that a decrease in the net and reduced price does not necessarily mean that the patient’s co-payment will be lower. The study singled out Pharmacy Benefit Managers, saying that companies “have been found to favor products with high list prices and large discounts over lower list price equivalents,” with “unintended consequences” for them. patients whose co-payment is based on the original list prices.

The Pharmaceutical Care Management Association, which represents Pharmacy Benefit Managers, blamed the manufacturers, noting that the high prices start there.

“Ironically, the industry that controls the list price of prescription drugs has tried to point the finger at those who focus on reducing the cost of prescription drugs to patients and payers,” the group said in a statement.

It’s true that manufacturers set original prices, says Rena Conti, professor at Boston University, associate research director of biopharmacy and public policy at the university’s Institute for Health System Innovation and Policy. . But she says the answer isn’t simply to penalize the profitable industry.

“There are a lot of very misaligned incentives that create a lot of headaches for real people at the pharmacy counter,” said Conti, who is due to testify on the matter before a House committee on Friday. “We are also the beneficiaries of a very robust pharmaceutical industry that is actually bringing new products to market, some of which are really transforming our lives. “

“The point here is not to punish but rather to really think about how we might have the opportunity to realign the incentives,” she adds. For patients paying thousands of dollars or more for essential medicines, this change cannot come soon enough.

read more
Prescription drugs

Prescription drug price hikes are slowing, but many patients say costs are still crippling

An Oregon law passed in 2018 requires drug companies and health insurers to file data with the state on prescription drug prices. Each year in December, this information is compiled into a report and released to lawmakers and the public.

In a virtual hearing on Wednesday, state officials gave an overview of some highlights of the 2021 report.

Numi Lee Griffith is Senior Policy Advisor at the Department of Consumer and Business Services. She said the data shows a sharp reduction in price increases reported in recent years.

“What we have seen is that there has been a decrease in the number of price increases,” she said, “as well as a decrease in the magnitude of the price increases”.

Griffith suggested that this is at least in part because drugmakers launched newer drugs at a higher price to begin with, so they have to report fewer increases to state officials later.

But according to testimony at the hearing, even with the easing of average price increases, people facing serious illnesses in the state are still struggling to afford their treatment.

Joan Morgan is part of the Oregon Coalition for Affordable Prescriptions. She said her father’s cancer drug had gone from an already unaffordable $ 4,000 to $ 10,000 a month. The only saving grace, she said, was a brother who brought the same medicine from Europe, where it cost $ 243.

“Think about it just for a second,” Morgan told the hearing panel lawmakers. “Do the math. Because it blows my mind even after we’ve been doing this for years.”

Other data highlights from the 2021 annual report include:

  • There were 193 new “expensive” drugs reported. These are drugs that are priced at wholesalers $ 670 or more for a 30 day supply.
  • The most expensive drugs in this group were the cancer chemotherapy drugs Abecma and Breyanzi, produced by Bristol-Meyers Squibb. They cost $ 419,500 and $ 410,300 respectively.
  • State data shows that, by far, cancer treatments make up most of the new high-cost drugs introduced.
  • 71 drugs reported annual price increases, the largest of which was a 778% increase for a generic drug from Nostrum Labs.
  • The average price increase for generic drugs was 27%, 13% for brand name drugs

The 2021 Prescription Drug Price Transparency Report is expected to be released on December 15.

read more
Medical supplies

Winston-Salem nurse pleads guilty to tampering with medical supplies | USAO-MDNC

GREENSBORO, NC – A woman in Winston-Salem pleaded guilty today to attempting to tamper with consumer products, said U.S. lawyer Sandra J. Hairston for the Central District of North Carolina.

According to court documents, Emilee Kathryn Poteat, 32, removed and opened packages containing vials of injectable hydromorphone from Novant Health Forsyth Medical Center (NHFMC) while employed as a contact nurse in the hospital. pre / post procedure clinical unit. From July 2020 to November 2020, Poteat withdrew vials for the purpose of converting and consuming hydromorphone by injecting the drug. Poteat then replaced the used vials with falsified vials containing saline solution. Poteat knew that by doing so, nurses at the NHFMC could unknowingly administer the contents of the compromised vials to patients.

Virginia Department of Health investigator Laura Pezzulo opened an investigation into Poteat’s handling of the drugs after the NHFMC provided vials they suspected were tampered with by Poteat. Poteat later admitted to tampering with injectable hydromorphone in an interview with investigator Pezzulo.

“The FDA oversees the drug supply to the United States to ensure that it is safe and effective, and those who knowingly tamper with the drugs put the health of patients at risk,” Special Agent in Charge Mark said. S. McCormack, FDA Office of Criminal Investigations Metro Washington Field Bureau. “We will continue to protect public health and bring to justice those healthcare professionals who take advantage of their unique position and compromise the health and comfort of their patients by tampering with the medications they need. “

US District Judge Loretta C. Biggs will set the sentence at a later date. Upon conviction, Poteat faces a maximum sentence of ten years in prison, a period of supervised release and financial penalties.

Sandra J. Hairston, United States Attorney for the Central District of North Carolina, made the announcement. Agents from the Food and Drug Administration / Criminal Investigations Division investigated the case. The case is being continued by Assistant US Attorney Frank J. Shhh.

###

read more
Medical products

3 actions to capitalize on the dynamism of the medical products industry

This story originally appeared on Zacks

The COVID-19 pandemic, which has proven to be a biological crisis of an unprecedented nature, has changed the very nature and dynamics of the healthcare industry. Zacks’ medical products industry has also not been immune to the pandemic, and has been hit hard by widespread supply chain disruptions and postponement of elective proceedings. However, the medical products space has seen a substantial recovery, mainly due to the easing of previous restrictions and the acceleration of vaccinations. Apart from this, the slow resumption of elective procedures, the growing demand for in vitro diagnostics (IVD) and the growing reliance on artificial intelligence (AI) and robotics are expected to favor industry participants. in the coming days. Despite a pandemic-induced disruption triggered by the Delta variant, particularly during August and September, industry players have yet to show signs of slowing down. Industry participants love Abbott Laboratories ABT, Bio-Rad Laboratories, Inc. BIO and Hill Rom Holdings, Inc. HRC are likely to take advantage of the factors mentioned above.

– Zack

5 actions in the process of doubling

Each has been handpicked by a Zacks expert as the # 1 favorite stock to earn + 100% or more in 2021. Previous recommendations have climbed + 143.0%, + 175.9%, +498 , 3% and + 673.0%.

Most of the stock in this report is flying under Wall Street’s radar, which provides a great opportunity to get into the ground floor.

Today, discover these 5 potential circuits >>

Want the latest recommendations from Zacks Investment Research? Today you can download 7 best stocks for the next 30 days. Click to get this free report

Abbott Laboratories (ABT): Free Stock Analysis Report

BioRad Laboratories, Inc. (BIO): Free Inventory Analysis Report

HillRom Holdings, Inc. (HRC): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks investment research

read more
Prescription drugs

ASHP wants to stop white bags on prescription drugs

The American Society of Health-System Pharmacists (ASHP) is working to end a practice known as “white bagging,” officials said.

White bagging is when a payer demands that providers can only source drugs from a limited selection of specialty pharmacies affiliated with the payer. In white sachets, pharmacies in the health system receive these drugs from specialized pharmacies which they must then dispense to patients. Typically, as part of the purchasing and billing system, pharmacies in the health system maintain their own inventories and prepare medications based on physicians’ electronic health records.

“We believe ASHP is compromising patient care,” said Kyle Robb, PharmD, state policy and advocacy associate at ASHP, during a presentation at the company’s virtual meeting in mid-year. White bags blind clinicians and hospitals to drug supply chains, can lead to delays in care and compromise electronic medical records, he added.

“White bagging has really emerged and gained momentum over the past couple of years,” noted Tom Kraus, MHS, vice president of government relations at ASHP.

In March, the ASHP and the American Hospital Association co-signed a letter to the FDA asking the agency to enforce the Drug Supply Chain Security Act (DSCSA) – which required that electronic chain histories supplies are maintained for all prescription drugs. until this drug is delivered to the patient – with the aim of ending the white bags.

“Our main argument with the FDA is that white bagging fundamentally bypasses the DSCSA,” Robb said. The DSCSA was adopted in 2013 in response to a meningitis outbreak in several states caused by contaminated steroids made at a compounding pharmacy in Massachusetts.

As part of white bagging, specialty pharmacies do not share transaction information with vendors, which means hospitals do not know the supply chain history of white bagged drugs. he explained.

However, the FDA has yet to take regulatory action regarding the white bags, Robb said.

The ASHP saw more state-level action for the first time this year, he noted. Prior to 2021, no state had white bag legislation, and only one state had introduced a bill in 2020. So far this year, 11 states have introduced white bag bills. Three states – Louisiana, Arkansas, and Virginia – have passed laws.

Louisiana’s law was passed in June and ensures that plans cannot refuse to pay a provider for the provision of clinician-administered drugs and cannot punish patients with additional fees, according to Robb. The law also requires that drugs in white sachets from specialized pharmacies be accompanied by a history of transactions.

In Arkansas, the new legislation takes a different approach to preventing white bags: it only applies to hematology and oncology patients, although the Arkansas Insurance Commissioner may extend the covered conditions. This law states that payers must cover both medical and pharmaceutical benefit channels, and that patients and providers can choose the billing channel that works best for them.

In Virginia, plans must allow unprivileged pharmacies to dispense drugs covered at network rates and cannot increase costs for patients who use unprivileged pharmacies. The Virginia Board of Pharmacy has also passed regulations on the storage and tracking of white bagged medications.

  • Lei Lei Wu is a news intern for Medpage Today. She is based in New Jersey. To follow

Disclosures

Robb and Kraus did not report any financial disclosures.

read more
Generic drugs

Corporate Rx for Distressed Healthcare System: Affordable Generics Made in USA

Nexus Pharmaceuticals founder Mariam Darsot believes in altruistic acts like funding a labor and delivery ward in Sierra Leone, the country with the highest maternal mortality rate in the world. Photograph of Evan Jenkins

Nexus Pharmaceuticals is a 2021 Inc. Best in Business winner. With the second annual Best in Business, Inc. award recognizes companies that have made an exceptional impact on their industries, communities, the environment and society as a whole.

Meet the Illinois-based family-owned pharmaceutical company investing in nationwide manufacturing of drugs as treatment for the struggling healthcare industry.

Nexus Pharmaceuticals unveiled a state-of-the-art manufacturing facility in Pleasant Prairie, Wisconsin in June, doubling down on its mission to make high-quality generic drugs more affordable and accessible to patients in the U.S. The company’s three-story building, an investment of $ 250 million that will eventually employ more than 400, is the first national project of its kind in three decades. Meanwhile, production of US pharmaceuticals has largely shifted overseas so companies can take advantage of reduced environmental regulations and a lower-cost workforce. Today, only 28 percent of the active pharmaceutical ingredients supplied to the United States are produced here.

This over-reliance on foreign manufacturers has resulted in supply chain issues, quality-related recalls, and reduced export availability. All of this has contributed to rising pharmaceutical prices and national shortages, according to Mariam Darsot, CEO and founder of Nexus. And that, she says, prevents people from getting the timely treatment they might need. Also at the start of the pandemic, Indian manufacturers reduced exports of more than 20 essential pharmaceuticals and active ingredients to meet patient demand in their own country, which only added to the already heavy burden. of American health. the care industry, explains Darsot.

“I think it’s fair to say that the pharmaceutical industry has damaged its reputation a lot through price fixing allegations, substandard products from overseas or price increases. essential drugs, ”Darsot said. And she is committed to changing the industry, from the inside out. Since its inception in 2003, Nexus has prioritized the production of injectable drugs with historically rare critical needs. It has a long history of working with contract manufacturers to produce its FDA-approved generic pharmaceuticals, and now, with its own manufacturing facility, it can scale up its production even further to have a serious impact on the overall drug supply of consumers. United States. (Especially considering the fact that most of the drug shortages in the country are in generic drugs, Nexus’ specialty, the promise is clear.)

Over the past year, the company has already increased the US supply of two rare and life-saving pharmaceuticals: an injection of succinylcholine chloride, a drug in high demand to treat Covid patients, and an injection of potassium chloride, an IV solution with historically few manufacturers (including the one damaged in Hurricane Maria, resulting in a lasting shortage).

Darsot says she’s not interested in profit for profit – the company explicitly produces drugs that are needed in an attempt to lower healthcare costs for consumers. Nexus avoids private equity so as not to be influenced by shareholders. His altruism also extends beyond his core business. In 2020, for example, Nexus funded a labor and delivery unit at the Tanihanun health center in Sierra Leone, the country with the highest maternal mortality rate in the world. In 2021, the company also donated $ 176,000 to charitable organizations through employee matchmaking and community partnerships.

“Being a family business allows us to give back to a community that has given so much to our business and our family,” said Darsot. “This brings us back to our core mission of helping deliver affordable medicines to those who need them most.”

EXPLORE MORE Best in business COMPANIESRectangle

Extract from the Winter 2021/2022 issue of Inc. Magazine

read more
Medical supplies

Utah Kids Foundation provides support and medical supplies to families in need

(KUTV) Melissa Christensen and Kim Butterfield both have medically fragile children. They also help run the Utah Kids Foundation.

“Our goal is to help and support families with children with special needs,” said Christensen, president of the foundation.

The nonprofit does a “supply swap” where it receives medical supplies and provides them to families who cannot afford them, are in dire need, or the insurance does not fully cover needed items.

“We get like pull-ups, underwear, underpants, diapers,” explained Butterfield, vice president of the organization. “We have almost all types of formulas available. “

Other supplies include feeding tube supplies, wipes, and whatever else people donate.

The Utah Kids Foundation also has a huge online support group for the families they serve.

“We have almost 6,000 families in our support group,” Christensen said.

The only requirements for joining the online group are to live in Utah or see a doctor in Utah. The needs range from children in full care to children with autism and ADHD issues.

Vanessa Whitehead used this support while caring for her daughter, Afton.

“They have been a huge resource for us,” she said.

The Utah Kids Foundation helps Whiteheads soon after Afton was born five years ago. They helped find a formula for Afton as well as feeding tubes.

Within the support group, Whitehead was able to ask questions of other parents, share advice herself, and celebrate milestones with fellow group members.

“It creates a tribe because there is no one who really understands a group like that,” she said.

The non-profit organization organizes events for children with disabilities, including Easter egg hunts, “birthday” celebrations and several Christmas events.

At the moment, they are collecting donations for Stuff the Stocking, which helps give gifts to these families.

“A lot of them have such a heavy financial burden because it is so expensive to raise a child with special needs and they need that help,” Christensen said.

All of the foundation’s members are volunteers and travel across the state helping families get the medical supplies they need. They keep the supplies in storage units from Cache Valley to the Nephi region. They also have a means of refueling all the way to St. George.

Christensen and Butterfield say their storage units are often overflowing with supplies and are looking for a larger space to store items.

Mountain America Credit Union donated $ 500 to the Utah Kids Foundation to help them meet their needs.

If you would like to help with their Stuff the Stocking event or if you would like to donate medical supplies, visit the Utah Kids Foundation website. You can also visit their Facebook page for more information.

read more